Document:

Registration Rights Agreement

 Exhibit 4.2 
 EXECUTION VERSION 
  
  
 Registration Rights Agreement

 Dated as of July 29, 2009 
 by and among 
 FREEDOM GROUP, INC. 
 and 
 the Subsidiary Guarantors listed on the Signature pages hereof, 

 on the one hand, 
 and 
 Banc of America Securities LLC, 
 Deutsche Bank Securities Inc., 
 Wells Fargo Securities, LLC 
 and 
 the other Initial Purchasers,

 on the other hand 
  
  

 REGISTRATION RIGHTS AGREEMENT 
 This REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made and entered into on July 29, 2009 (the “Closing
Date”), by and among FREEDOM GROUP, INC., a Delaware corporation (the “Company”), and the subsidiary guarantors listed on the signature page of this Agreement (the “Subsidiary Guarantors”), on the
one hand, and Banc of America Securities LLC, Deutsche Bank Securities Inc. and Wells Fargo Securities, LLC, on behalf of themselves and as representatives of each of the other Initial Purchasers named in Schedule A hereto (collectively, the
“Initial Purchasers”), on the other hand. 
 This Agreement is made pursuant to that certain Purchase
Agreement, dated July 15, 2009 by and among the Company, the Subsidiary Guarantors and the Initial Purchasers (the “Purchase Agreement”), which provides for the sale by the Company to the Initial Purchasers of an aggregate of
$200,000,000 in principal amount of the Company’s 101/4% Senior Secured Notes
due 2015 (the “Notes”), which are guaranteed by the Subsidiary Guarantors. In order to induce the Initial Purchasers to enter into the Purchase Agreement, the Company and the Subsidiary Guarantors have agreed to provide to the
Initial Purchasers and their direct and indirect transferees the registration rights set forth in this Agreement. The execution of this Agreement is a condition to the closing under the Purchase Agreement. 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual promises contained herein, and for other good and valuable
consideration, the receipt and sufficiency of which are acknowledged, the parties hereto covenant and agree as follows: 
 1.
Definitions. 
 As used in this Agreement, the following capitalized defined terms shall have the following meanings:

 “1933 Act” shall mean the Securities Act of 1933, as amended from time to time. 
 “1934 Act” shall mean the Securities Exchange Act of 1934, as amended from time to time. 
 “Additional Guarantor” shall mean any subsidiary of the Company that executes a Subsidiary Guarantee under the Indenture after the date
of this Agreement. 
 “Additional Interest” shall have the meaning set forth in Section 2.5(a) hereof.

 “Automatic Shelf Registration Statement” shall mean an “automatic shelf registration statement” as that term is
defined in Rule 405, as amended, under the 1933 Act. 
 “Business Day” shall mean any day that is not a Saturday, Sunday or
other day on which commercial banks in New York City are authorized or required by law to remain closed. 
 “Closing” shall
mean the Closing Date as defined in the Purchase Agreement. 

 “Company” shall have the meaning set forth in the preamble and shall also include the
Company’s successors. 
 “Depositary” shall mean The Depository Trust Company, or any other depositary appointed by the
Company, provided, however, that such depositary must have an address in the Borough of Manhattan, in the City of New York. 
 “Effectiveness Period” shall have the meaning set forth in Section 2.2(b). 
 “Event
Date” shall have the meaning set forth in Section 2.5(b). 
 “Exchange Dates” shall have the meaning
set forth in Section 2.1. 
 “Exchange Notes” shall mean the new notes to be exchanged for Transfer Restricted
Notes, not subject to restrictions on transfer in the United States. 
 “Exchange Offer” shall mean the exchange offer by
the Company and the Subsidiary Guarantors of Exchange Notes for Transfer Restricted Notes pursuant to Section 2.1 hereof. 
 “Exchange Offer Registration” shall mean a registration under the 1933 Act effected pursuant to Section 2.1 hereof. 
 “Exchange Offer Registration Statement” shall mean an exchange offer registration statement on Form S-4 (or, if applicable, on another appropriate form), and all amendments and supplements to such
registration statement, including the Prospectus contained therein, all exhibits thereto and all documents incorporated by reference therein. 
 “Free Writing Prospectus” means each free writing prospectus (as defined in Rule 405 under the 1933 Act) prepared by or on behalf of the Company or used or referred to by the Company in connection with the sale of the Notes
or the Exchange Notes. 
 “Freely Tradable” shall mean, with respect to a Note, a Note that at any time of determination
(i) may be resold to the public in accordance with Rule 144 under the 1933 Act or any successor provision thereof (“Rule 144”) without regard to volume, manner of sale or any other restrictions contained in Rule
144 (other than the holding period requirement in paragraph (d)(1)(ii) of Rule 144 so long as such holding period requirement is satisfied at such time of determination), (ii) does not bear any restrictive legends relating to the 1933 Act and
(iii) does not bear a restricted CUSIP number. 
 “Holder” shall mean an Initial Purchaser, for so long as it owns any
Transfer Restricted Notes, and each of its successors, assigns and direct and indirect transferees who become registered owners of Transfer Restricted Notes under the Indenture and each Participating Broker-Dealer that holds Exchange Notes for so
long as such Participating Broker-Dealer is required to deliver a prospectus meeting the requirements of the 1933 Act in connection with any resale of such Exchange Notes. 
  

 -2- 

 “Indenture” shall mean the Indenture relating to the Notes, dated as of July 29,
2009, among the Company, the Subsidiary Guarantors, and Wilmington Trust, FSB, as trustee and collateral agent, as the same may be amended, supplemented, waived or otherwise modified from time to time in accordance with the terms thereof.

 “Initial Purchaser” or “Initial Purchasers” shall have the meaning set forth in the preamble.

 “Issuer Information” shall have the meaning set forth in Section 4(a)(i). 
 “Majority Holders” shall mean the Holders of a majority of the aggregate principal amount of outstanding Transfer Restricted Notes;
provided that whenever the consent or approval of Holders of a specified percentage of Transfer Restricted Notes is required hereunder, Transfer Restricted Notes held by the Company and other obligors on the Notes or any Affiliate (as defined
in the Indenture) of the Company or any Subsidiary Guarantor shall be disregarded in determining whether such consent or approval was given by the Holders of such required percentage amount; provided, further, that if the Company shall
issue any additional Notes under the Indenture prior to consummation of the Exchange Offer, or if applicable, prior to the effectiveness of any Shelf Registration Statement or prior to the Transfer Restricted Notes otherwise becoming Freely
Tradable, such additional Notes and the Transfer Restricted Notes to which this Agreement relates shall be treated together as one class for purposes of determining whether the consent or approval of Holders of a specified percentage of Transfer
Restricted Notes has been obtained. 
 “Notes” shall have the meaning set forth in the preamble hereof. 
 “Participating Broker-Dealer” shall mean any of the Initial Purchasers and any other broker-dealer which makes a market in the Notes and
exchanges Transfer Restricted Notes in the Exchange Offer for Exchange Notes. 
 “Person” shall mean an individual,
partnership (general or limited), corporation, limited liability company, trust or unincorporated organization, or a government or agency or political subdivision thereof. 
 “Prospectus” shall mean the prospectus included in, or, pursuant to the rules and regulations of the 1933 Act, deemed a part of, a
Registration Statement, including any preliminary prospectus, and any such prospectus as amended or supplemented by any prospectus supplement, including any such prospectus supplement with respect to the terms of the offering of any portion of the
Transfer Restricted Notes covered by a Shelf Registration Statement, and by all other amendments and supplements to a prospectus, including post-effective amendments, and in each case including all material incorporated by reference therein.

 “Purchase Agreement” shall have the meaning set forth in the preamble. 
 “Registration Default” shall have the meaning set forth in Section 2.5(a). 
  

 -3- 

 “Registration Expenses” shall mean any and all expenses incident to performance of or
compliance by the Company and the Subsidiary Guarantors with this Agreement, including without limitation: (i) all SEC, stock exchange or Financial Industry Regulatory Authority (“FINRA”) registration and filing fees,
including, if applicable, the fees and expenses of any “qualified independent underwriter” that is required to be retained by any holder of Transfer Restricted Notes in accordance with the rules and regulations of FINRA, (ii) all fees
and expenses incurred in connection with compliance with state securities or blue sky laws and compliance with the rules of FINRA (including reasonable fees and disbursements of counsel for any underwriters or Holders in connection with blue sky
qualification of any of the Exchange Notes or Transfer Restricted Notes and any filings with FINRA), (iii) all expenses of any Persons in preparing or assisting in preparing, word processing, printing and distributing any Registration
Statement, any Prospectus, any amendments or supplements thereto, any underwriting agreements, securities sales agreements and other documents relating to the performance of and compliance with this Agreement, (iv) all fees and expenses
incurred in connection with the listing, if any, of any of the Transfer Restricted Notes on any securities exchange or exchanges, (v) all rating agency fees, (vi) the fees and disbursements of counsel for the Company and the Subsidiary
Guarantors and of the independent public accountants of the Company and the Subsidiary Guarantors, including the expenses of any special audits or “cold comfort” letters required by or incident to such performance and compliance, and in
the case of a Shelf Registration Statement, the reasonable fees and disbursements of one counsel for the Holders as a group (which counsel shall be selected by the Majority Holders and which counsel may also be counsel for the Initial Purchasers),
(vii) the fees and expenses of the Trustee (including the reasonable fees and disbursements of its counsel), and any escrow agent or custodian, (viii) all fees and disbursements relating to the qualification of the Indenture under
applicable securities laws, and (ix) any fees and disbursements of the underwriters customarily required to be paid by issuers or sellers of securities and the fees and expenses of any special experts retained by the Company and the Subsidiary
Guarantors in connection with any Registration Statement, but excluding underwriting discounts and commissions and transfer taxes, if any, relating to the sale or disposition of Transfer Restricted Notes by a Holder. Notwithstanding the foregoing,
except as specifically provided above, the Company and the Subsidiary Guarantors shall not be responsible for the fees and expenses of the Initial Purchasers in connection with the Exchange Offer, or the fees and expenses of counsel to the Initial
Purchasers in connection therewith. 
 “Registration Statement” shall mean any registration statement of the Company and the
Subsidiary Guarantors which covers any of the Exchange Notes or Transfer Restricted Notes pursuant to the provisions of this Agreement, and all amendments and supplements to any such Registration Statement, including post-effective amendments, in
each case including the Prospectus contained therein or deemed a part thereof, all exhibits thereto and all material incorporated by reference therein. 
 “Registration Trigger Date” means the fifth Business Day following the one year anniversary of the date hereof. 
 “SEC” shall mean the Securities and Exchange Commission or any successor agency or government body performing the functions currently performed by the United States Securities and Exchange Commission.

  

 -4- 

 “Shelf Registration” shall mean a registration effected pursuant to
Section 2.2. 
 “Shelf Registration Statement” shall mean a “shelf” registration statement of the
Company and the Subsidiary Guarantors pursuant to the provisions of Section 2.2, including an Automatic Shelf Registration Statement, if applicable, which covers all or a portion of the Transfer Restricted Notes on an appropriate form
under Rule 415 under the 1933 Act, or any similar rule that may be adopted by the SEC, and all amendments and supplements to such registration statement, including post-effective amendments, in each case including the Prospectus contained therein or
deemed a part thereof, all exhibits thereto and all material incorporated by reference therein. 
 “Shelf Request” shall
have the meaning set forth in Section 2.2(a)(ii). 
 “Subsidiary Guarantees” shall mean the guarantees of the
Notes and the Exchange Notes by the Subsidiary Guarantors under the Indenture. 
 “Subsidiary Guarantors” shall have the
meaning set forth in the preamble and shall also include any Subsidiary Guarantor’s successors and any Additional Guarantors. 
 “TIA” shall have the meaning set forth in Section 2.1(d) hereof. 
 “Transfer Restricted
Notes” shall mean the Notes; provided, however, that the Notes shall cease to be Transfer Restricted Notes on the earliest to occur of (i) the date on which a Registration Statement with respect to such Notes has become
effective under the 1933 Act and such Notes have been exchanged or disposed of pursuant to such Registration Statement, (ii) the date on which such Notes cease to be outstanding under the Indenture or (iii) the date on which such Notes are
Freely Tradable. 
 “Trustee” shall mean the trustee with respect to the Notes under the Indenture. 
 “Underwriter” shall have the meaning set forth in Section 4(a). 
 “WKSI” shall mean a “well-known seasoned issuer” as that term is defined in Rule 405, as amended, under the 1933 Act.

 2. Registration Under the 1933 Act. 
 2.1 Exchange Offer. 
 (a) To the extent not prohibited by any applicable law or applicable
interpretations of the staff of the SEC, with respect to any Notes, if any, that on the Registration Trigger Date are Transfer Restricted Notes, the Company and the Subsidiary Guarantors shall use commercially reasonable efforts to (X) cause to
be filed and to become effective an Exchange Offer Registration Statement covering an offer to the Holders to exchange all the Transfer Restricted Notes for Exchange Notes and (Y) have such Registration Statement remain effective until 90 days
after the last Exchange Date for use by one or more Participating Broker Dealers if one or more broker dealers notify the Company in writing that they anticipate that they will be Participating Broker 

  

 -5- 

 
Dealers. The Company and the Subsidiary Guarantors shall commence the Exchange Offer promptly after the Exchange Offer Registration Statement is declared
effective by the SEC and use commercially reasonable efforts to complete the Exchange Offer not later than 45 days after such effective date. 
 (b) The Company and the Subsidiary Guarantors shall, for the benefit of the Holders, at the Company’s and Subsidiary Guarantors’ cost, commence the Exchange Offer, if any, by mailing the related Prospectus, appropriate letters of
transmittal and other accompanying documents to each Holder stating, in addition to such other disclosures as are required by applicable law, substantially the following: 
 (i) that the Exchange Offer is being made pursuant to this Agreement and that all Transfer Restricted Notes validly tendered and not
properly withdrawn will be accepted for exchange; 
 (ii) the dates of acceptance for exchange (which shall be a period of at
least 20 Business Days from the date such notice is mailed) (the “Exchange Dates”); 
 (iii) that any
Transfer Restricted Notes not tendered will remain outstanding and continue to accrue interest but will not retain any rights under this Agreement, except as otherwise specified herein; 
 (iv) that any Holder electing to have a Transfer Restricted Note exchanged pursuant to the Exchange Offer will be required to
(A) surrender such Transfer Restricted Note, together with the appropriate letters of transmittal, to the institution and at the address (located in the Borough of Manhattan, The City of New York) and in the manner specified in the notice, or
(B) effect such exchange otherwise in compliance with the applicable procedures of the Depositary, in each case prior to the close of business on the last Exchange Date; and 
 (v) that any Holder will be entitled to withdraw its election, not later than the close of business on the last Exchange Date, by
(A) sending to the institution and at the address specified in the notice, a telegram, telex, facsimile transmission or letter setting forth the name of such Holder, the principal amount of Transfer Restricted Notes delivered for exchange and a
statement that such Holder is withdrawing its election to have such Transfer Restricted Notes exchanged or (B) effecting such withdrawal in compliance with the applicable procedures of the Depositary. 
 (c) Upon the effectiveness of the Exchange Offer Registration Statement, if any, the Company and the Subsidiary Guarantors shall promptly commence the
Exchange Offer, it being the objective of such Exchange Offer to enable each Holder eligible and electing to exchange Transfer Restricted Notes for Exchange Notes (assuming that such Holder makes representations and warranties to the Company that
(a) it is not an affiliate of the Company within the meaning of Rule 405 under the 1933 Act or, if an affiliate, such Holder will comply with the registration and prospectus delivery requirements of the 1933 Act and will provide information to
be included in a Shelf Registration Statement in order to have its Exchange Notes included in such Shelf Registration Statement, (b) any Exchange Notes to be received by it will be acquired in the 

  

 -6- 

 
ordinary course of its business, (c) if such Holder is not a broker-dealer, that it is not engaged in, and does not intend to engage in, the
distribution of the Exchange Notes, (d) if such Holder is a broker-dealer that will receive Exchange Notes for its own account in exchange for Transfer Restricted Notes acquired as a result of market-making or other trading activities, then
such broker-dealer will deliver a prospectus (or, to the extent permitted by law, make available a Prospectus) in connection with any resale of such Exchange Notes, and (e) it has no arrangements or understandings with any Person to participate
in the distribution of the Transfer Restricted Notes or the Exchange Notes) to transfer such Exchange Notes from and after their receipt without any limitations or restrictions under the 1933 Act and under state securities or blue sky laws.

 (d) The Exchange Notes, if any, shall be issued under (i) the Indenture or (ii) an indenture identical in all material respects
to the Indenture and which, in either case, has been qualified under the Trust Indenture Act of 1939, as amended (the “TIA”), or is exempt from such qualification and shall provide that the Exchange Notes shall not be subject to the
transfer restrictions set forth in the Indenture. The Exchange Notes and the Notes shall vote and consent together on all matters as one class and none of the Exchange Notes or the Notes will have the right to vote or consent as a separate class on
any matter. 
 (e) As soon as practicable after the close of the Exchange Offer, the Company and the Subsidiary Guarantors shall: 

(i) accept for exchange all Transfer Restricted Notes duly tendered and not validly withdrawn pursuant to the Exchange Offer in
accordance with the terms of the Exchange Offer Registration Statement and the letter of transmittal which shall be an exhibit thereto; 
 (ii) deliver to the Trustee for cancellation all Transfer Restricted Notes so accepted for exchange; and 
 (iii) cause the Trustee promptly to authenticate and deliver Exchange Notes to each Holder of Transfer Restricted Notes so accepted for exchange in a principal amount equal to the principal amount of the Transfer
Restricted Notes of such Holder so accepted for exchange. 
 (f) Interest on each Exchange Note, including Additional
Interest, will accrue (a) from the later of (i) the last date on which interest was paid on the Transfer Restricted Notes surrendered in exchange therefor or (ii) if the Transfer Restricted Notes are surrendered for exchange on a date
in a period which includes the record date for an interest payment date to occur on or after the date of such exchange and as to which interest will be paid, the date of such interest payment date or (b) if no interest has been paid on the
Transfer Restricted Notes, from the date of issuance. If requested in writing the Company shall inform the Initial Purchasers of the names and addresses of the Holders to whom the Exchange Offer is made, and the Initial Purchasers shall have the right, but not the obligation, to contact such Holders and otherwise
facilitate the tender of Transfer Restricted Notes in the Exchange Offer. 
 (g) The Company and the Subsidiary
Guarantors shall use commercially reasonable efforts to complete the Exchange Offer as provided above and shall comply with the applicable 

  

 -7- 

 
requirements of the 1933 Act, the 1934 Act and other applicable laws and regulations in connection with the Exchange Offer. The Offer shall not be subject to
any conditions, other than (1) the Exchange Offer does not violate any applicable law or applicable interpretations of the staff of the SEC, (2) no action or proceeding shall have been instituted or threatened in any court or by any
governmental agency with respect to the Exchange Offer and (3) all governmental approvals shall have been obtained that the Company deems necessary for the consummation of the Exchange Offer. 
 2.2 Shelf Registration. 
 (a)
If, 
 (i) the Company and the Subsidiary Guarantors would otherwise be required to consummate an Exchange Offer Registration
pursuant to Section 2.1 but determine that such Exchange Offer Registration is not available or the Exchange Offer may not be completed as soon as practicable after the last Exchange Date because it would violate any applicable law, SEC
rules and regulations or any interpretation of the staff of the SEC, 
 (ii) the Exchange Offer is not for any other reason
completed by the 45th day following the date the Exchange Offer Registration Statement is declared effective, or 
 (iii) any
Initial Purchaser notifies the Company that it holds Transfer Restricted Notes that, in the opinion of counsel for such Holder, are not Freely Tradable on the Registration Trigger Date (a “Shelf Request”), 
 the Company and the Subsidiary Guarantors shall promptly deliver to the Holders and the Trustee written notice thereof and shall use commercially
reasonable efforts to cause to be filed as soon as practicable after such determination, date or Shelf Request, as the case may be, a Shelf Registration Statement providing for the sale of all the Transfer Restricted Notes by the Holders thereof and
to have such Shelf Registration Statement become effective by the 90th day following
such determination, date or Shelf Request. 
 (b) In the event that the Company and the Subsidiary Guarantors are required to file a Shelf
Registration Statement pursuant to a Shelf Request, the Company and the Subsidiary Guarantors shall use commercially reasonable efforts to file and have become effective a Shelf Registration Statement with respect to offers and sales of Transfer
Restricted Notes after the completion of the Exchange Offer and an Exchange Offer Registration Statement if otherwise required pursuant to this Agreement. In the event that the Company and the Subsidiary Guarantors are required to file a Shelf
Registration Statement, the Company and the Subsidiary Guarantors agree to use commercially reasonable efforts to keep the Shelf Registration Statement continuously effective, supplemented and amended (including through post-effective amendments on
Form S-3 if the Company is eligible to use such Form) until the date that is one year from the date the Shelf Registration Statement is declared effective or such shorter period ending when no Notes covered by such Shelf Registration Statement
constitute Transfer Restricted Notes (the “Effectiveness Period”). 
  

 -8- 

 (c) Notwithstanding any other provisions hereof, the Company and the Subsidiary Guarantors shall use
commercially reasonable efforts to ensure that (i) any Shelf Registration Statement and any amendment thereto and any Prospectus forming a part thereof and any supplement thereto complies in all material respects with the 1933 Act and the rules
and regulations thereunder, (ii) any Shelf Registration Statement and any amendment thereto does not, when it becomes effective, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or
necessary to make the statements therein not misleading and (iii) any Prospectus forming part of any Shelf Registration Statement, and any supplement to such Prospectus (as amended or supplemented from time to time), does not include an untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements, in light of the circumstances under which they were made, not misleading. 
 (d) The Company and the Subsidiary Guarantors shall not permit any securities other than Transfer Restricted Notes to be included in the Shelf
Registration Statement; provided, however, that if the offer and sale of the Transfer Restricted Notes is registered pursuant to an Automatic Shelf Registration Statement, the foregoing prohibition shall apply only to the supplement or
amendment covering such registration. The Company and the Subsidiary Guarantors agree, if necessary, to supplement or amend the Shelf Registration Statement, as required by Section 3(b) below. 
 (e) If the Company is obligated to file a Shelf Registration Statement pursuant to this Section 2.2, and at the time such obligation arises,
the Company is a WKSI, then, in lieu of filing such Shelf Registration Statement, the Company shall file an Automatic Shelf Registration Statement or supplement or amend an existing Automatic Shelf Registration Statement, as appropriate, to include
the offer and sale of the Transfer Restricted Notes by the Holders from time to time in accordance with the methods of distribution elected by the Holders of a majority in aggregate principal amount of Transfer Restricted Notes participating in such
registration and set forth in such Automatic Shelf Registration Statement (or supplement or amendment thereto), within the time frame specified in this Section 2.2. 
 2.3 Expenses. The Company and the Subsidiary Guarantors shall pay all Registration Expenses in connection with the registration pursuant to
Sections 2.1 and 2.2. Each Holder shall pay all underwriting discounts and commissions and transfer taxes, if any, relating to the sale or disposition of such Holder’s Transfer Restricted Notes pursuant to the Shelf Registration
Statement. 
 2.4 Effectiveness. 
 (a) The Company and the Subsidiary Guarantors will be deemed not to have used commercially reasonable efforts to cause the Exchange Offer Registration Statement or the Shelf Registration Statement, as the case may be,
to become, or to remain, effective during the requisite period if either the Company or any Subsidiary Guarantor voluntarily takes any action that would, or omits to take any action which omission would, result in any such Registration Statement not
being declared effective, or in the Holders of Transfer Restricted Notes covered thereby not being able to exchange or offer and sell such Transfer Restricted Notes during that period as and to the extent contemplated hereby, unless such action is
required by applicable law, in each case other than under the circumstances described in Sections 3(e)(iii), (iv), (v) or (vi) below. 
  

 -9- 

 (b) Neither an Exchange Offer Registration Statement pursuant to Section 2.1 hereof nor a
Shelf Registration Statement pursuant to Section 2.2 hereof, if not otherwise effective upon filing with the SEC as provided by Rule 462, will be deemed to have become effective unless it has been declared effective by the SEC;
provided, however, that if, after it becomes effective, the offering of Transfer Restricted Notes pursuant to an Exchange Offer Registration Statement or a Shelf Registration Statement is interfered with by any stop order, injunction
or other order or requirement of the SEC or any other governmental agency or court, such Registration Statement will not be effective during the period of such interference, until the offering of Transfer Restricted Notes pursuant to such
Registration Statement may legally resume. 
 2.5 Additional Interest. 
 (a) In the event that (i) an Exchange Offer Registration Statement is required pursuant to Section 2.1 and
(x) such Exchange Offer Registration Statement does not become effective on or prior to the two year anniversary of the date hereof or (y) the Exchange Offer is not completed within 45 days after the date on which the Exchange Offer
Registration Statement becomes effective, or (ii) a Shelf Registration Statement is required in accordance with Section 2.2 and such Shelf Registration Statement (x) does not become effective on or prior to the 90th day following (A) the date of such determination, in the case of a Shelf Registration
Statement required pursuant to Section 2.2(a)(i), (B) such date, in the case of a Shelf Registration Statement required pursuant to Section 2.2(a)(ii) (which in no event shall be earlier than the date the Exchange Offer
Registration Statement is required to be declared effective pursuant to clause 2.5(a)(i)(x) above) or (C) the date of such Shelf Request, in the case of a Shelf Registration Statement required pursuant to Section 2.2(a)(iii), or
(y) becomes effective but ceases to be effective or the corresponding Prospectus ceases to be usable at any time during the Effectiveness Period, and such failure to remain effective or usable exists for more than 60 days (whether or not
consecutive) in any 12-month period (any event referred to in the foregoing clauses (i) or (ii) a “Registration Default”), then, in each case, the interest rate on the Transfer Restricted Notes will be
increased by (i) 0.25% per annum for the first 90-day period immediately following such Registration Default and (ii) an additional 0.25% per annum with respect to each subsequent 90-day period, up to a maximum of 1.00% per
annum, in each case until the earlier of the date such Registration Default is cured or the date on which no Notes constitute Transfer Restricted Notes. Any amounts payable under this paragraph shall also be deemed “Additional
Interest” for purposes of this Agreement. 
 (b) The Company shall notify the Trustee within three business days after each and
every date on which an event occurs in respect of which Additional Interest is required to be paid (an “Event Date”). Any Additional Interest due shall be payable on each interest payment date to the Holder of Notes with respect to
which Additional Interest is due and owing. Each obligation to pay Additional Interest shall be deemed to accrue from and including the day following the applicable Event Date. 
  

 -10- 

 3. Registration Procedures. 
 In connection with the obligations of the Company and the Subsidiary Guarantors with respect to Registration Statements pursuant to Sections 2.1
and 2.2 hereof, the Company and the Subsidiary Guarantors shall: 
 (a) prepare and file with the SEC a Registration
Statement, within the relevant time periods specified in Section 2, on the appropriate form under the 1933 Act and the rules promulgated thereunder, which form (i) shall be selected by the Company, (ii) shall, in the case of a
Shelf Registration, be available for the sale of the Transfer Restricted Notes by the selling Holders thereof, (iii) shall comply as to form in all material respects with the requirements of the applicable form and include or incorporate by
reference all financial statements required by the SEC to be filed therewith or incorporated by reference therein and (iv) shall comply in all respects with the requirements of Regulation S-T under the 1933 Act, and use commercially reasonable
efforts to cause such Registration Statement to become effective and remain effective for the applicable period in accordance with Section 2 hereof, 
 (b) prepare and file with the SEC such amendments and post-effective amendments to each Registration Statement as may be necessary under
applicable law to keep such Registration Statement effective for the applicable period; and cause each Prospectus to be supplemented by any required prospectus supplement, and as so supplemented to be filed pursuant to Rule 424 (or any similar
provision then in force) under the 1933 Act and comply with the provisions of the 1933 Act, the 1934 Act and the rules and regulations thereunder applicable to them with respect to the disposition of all securities covered by each Registration
Statement during the applicable period in accordance with the intended method or methods of distribution by the selling Holders thereof (including sales by any Participating Broker-Dealer); and keep each Prospectus current during the period
described in Section 4(3) of and Rule 174 under the 1933 Act that is applicable to transactions by brokers or dealers with respect to the Transfer Restricted Notes or Exchange Notes; 
 (c) in the case of a Shelf Registration, (i) notify each Holder of Transfer Restricted Notes to be covered thereby, at least five
business days prior to filing, that a Shelf Registration Statement (except in the case of an Automatic Shelf Registration Statement, in which case at least five business days prior to the inclusion of information regarding selling security holders
in the Prospectus forming a part of such Automatic Shelf Registration Statement) with respect to such Transfer Restricted Notes is being filed and advising such Holders that the distribution of such Transfer Restricted Notes will be made in
accordance with the method selected by a majority in aggregate principal amount of the Holders of Transfer Restricted Notes participating in the Shelf Registration; (ii) furnish to each Holder of Transfer Restricted Notes to be covered thereby
and to each underwriter of an underwritten offering of Transfer Restricted Notes, if any, without charge, as many copies of each Prospectus, including each preliminary Prospectus, and any amendment or supplement thereto and such other documents as
such Holder or underwriter may reasonably request, including financial statements and schedules and, if the Holder so requests, all exhibits in order to facilitate the public sale or other disposition of the Transfer Restricted Notes; and
(iii) do hereby consent to the use of the Prospectus or any amendment or supplement thereto by each of the selling Holders of Transfer Restricted Notes in connection with the offering and sale of the Transfer Restricted Notes covered by the
Prospectus or any amendment or supplement thereto; 
  

 -11- 

 (d) use commercially reasonable efforts to register or qualify the Transfer Restricted
Notes under all applicable state securities or “blue sky” laws of such jurisdictions as any Holder of Transfer Restricted Notes covered by a Registration Statement and each underwriter of an underwritten offering of Transfer Restricted
Notes shall reasonably request by the time the applicable Registration Statement is declared effective by the SEC, cooperate with such Holders in connection with any filings required to be made with FINRA, and do any and all other acts and things
which may be reasonably necessary or advisable to enable each such Holder and underwriter to consummate the disposition in each such jurisdiction of such Transfer Restricted Notes owned by such Holder; provided, however, that the
Company and the Subsidiary Guarantors shall not be required to (i) qualify as a foreign corporation or as a dealer in securities in any jurisdiction where they would not otherwise be required to qualify but for this Section 3(d), or
(ii) take any action which would subject them to general service of process or taxation in any such jurisdiction where they are not then so subject; 
 (e) notify promptly each Holder of Transfer Restricted Notes under a Shelf Registration or any Participating Broker-Dealer who has notified the Company that it is utilizing the Exchange Offer Registration Statement as
provided in clause (f) below and, if requested by such Holder or Participating Broker-Dealer, confirm such advice in writing promptly (i) when a Registration Statement has become effective and when any post-effective amendments and
supplements to a Registration Statement have become effective, (ii) of any request by the SEC or any state securities authority for post-effective amendments and supplements to a Registration Statement and Prospectus or for additional
information after the Registration Statement has become effective, (iii) of the issuance by the SEC or any state securities authority of any stop order suspending the effectiveness of a Registration Statement or the initiation of any
proceedings for that purpose, including the receipt by the Company of any notice of objection of the SEC to the use of a Shelf Registration Statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the 1933 Act, (iv) in
the case of a Shelf Registration, if, between the effective date of a Registration Statement and the closing of any sale of Transfer Restricted Notes covered thereby, the representations and warranties of the Company and the Subsidiary Guarantors
contained in any underwriting agreement, securities sales agreement or other similar agreement, if any, relating to the offering cease to be true and correct in all material respects, (v) of the happening of any event or the discovery of any
facts during the period a Shelf Registration Statement is effective which makes any statement made in such Registration Statement or the related Prospectus untrue in any material respect or which requires the making of any changes in such
Registration Statement or Prospectus in order to make the statements therein not misleading, (vi) of the receipt by the Company of any notification with respect to the suspension of the qualification of the Transfer Restricted Notes or the
Exchange Notes, as the case may be, for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose and (vii) of any determination by the Company that a post-effective amendment to such Registration Statement
would be appropriate; 
 (f) in the case of the Exchange Offer Registration Statement (i) include in the Exchange Offer
Registration Statement a section entitled “Plan of Distribution” which 

  

 -12- 

 
section shall be in customary form, and which shall contain a summary statement of the positions taken or policies made by the staff of the SEC with respect
to the potential “underwriter” status of any broker-dealer that holds Transfer Restricted Notes acquired for its own account as a result of market-making activities or other trading activities and that will be the beneficial owner (as
defined in Rule 13d-3 under the 1934 Act) of Exchange Notes to be received by such broker-dealer in the Exchange Offer, whether such positions or policies have been publicly disseminated by the staff of the SEC or such positions or policies,
represent the prevailing views of the staff of the SEC, including a statement that any such broker dealer who receives Exchange Notes for Transfer Restricted Notes pursuant to the Exchange Offer may be deemed a statutory underwriter and must deliver
a prospectus meeting the requirements of the 1933 Act in connection with any resale of such Exchange Notes, (ii) furnish to each Participating Broker-Dealer who has delivered to the Company the notice referred to in Section 3(e),
without charge, as many copies of each Prospectus included in the Exchange Offer Registration Statement, including any preliminary prospectus, and any amendment or supplement thereto, as such Participating Broker Dealer may reasonably request,
(iii) do hereby consent to the use of the Prospectus forming part of the Exchange Offer Registration Statement or any amendment or supplement thereto, by any Person subject to the prospectus delivery requirements of the SEC, including all
Participating Broker-Dealers, in connection with the sale or transfer of the Exchange Notes covered by the Prospectus or any amendment or supplement thereto, and (iv) include in the transmittal letter or similar documentation to be executed by
an exchange offeree in order to participate in the Exchange Offer (x) the following provision: 
 “If the exchange offeree is a
broker-dealer holding Transfer Restricted Notes acquired for its own account as a result of market-making activities or other trading activities, it will deliver a prospectus meeting the requirements of the 1933 Act in connection with any resale of
Exchange Notes received in respect of such Transfer Restricted Notes pursuant to the Exchange Offer;” and 
 (y) a statement to the
effect that by a broker-dealer’s making the acknowledgment described in clause (x) and by delivering a Prospectus in connection with the exchange of Transfer Restricted Notes, the broker-dealer will not be deemed to admit that it is
an underwriter within the meaning of the 1933 Act; 
 (g) use commercially reasonable efforts to obtain the withdrawal of any
order suspending the effectiveness of a Registration Statement at the earliest practicable moment, and, in the case of a Shelf Registration, the resolution of any objection of the SEC pursuant to Rule 401(g)(2), including by filing an amendment to
such Shelf Registration Statement on the proper form, at the earliest possible moment and provide immediate notice to each Holder of the withdrawal of any such order or such resolution; 
 (h) in the case of a Shelf Registration, if requested in writing, furnish to each Holder of Transfer Restricted Notes, and each
underwriter, if any, without charge, at least one conformed copy of each Registration Statement and any post-effective amendment thereto, including financial statements and schedules (without documents incorporated therein by reference and all
exhibits thereto, unless requested); 
  

 -13- 

 (i) in the case of a Shelf Registration, cooperate with the selling Holders of Transfer
Restricted Notes to facilitate the timely preparation and delivery of certificates representing Transfer Restricted Notes to be sold and not bearing any restrictive legends; and enable such Transfer Restricted Notes to be in such denominations
(consistent with the provisions of the Indenture) and registered in such names as the selling Holders or the underwriters, if any, may reasonably request at least three business days prior to the closing of any sale of Transfer Restricted Notes;

 (j) in the case of a Shelf Registration, upon the occurrence of any event or the discovery of any facts, each as
contemplated by Sections 3(e)(v) and 3(e)(vi) hereof, as promptly as practicable after the occurrence of such an event, use commercially reasonable efforts to prepare and file with the SEC a supplement or post-effective amendment to
the Registration Statement or the related Prospectus or any document incorporated therein by reference or file any other required document so that, as thereafter delivered to the purchasers of the Transfer Restricted Notes or Participating
Broker-Dealers, such Prospectus will not contain at the time of such delivery any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which they were
made, not misleading or will remain so qualified; 
 (k) in the case of a Shelf Registration Statement, a reasonable time
prior to the filing of any Registration Statement, any Prospectus, any amendment to a Registration Statement or amendment or supplement to a Prospectus or of any document that is to be incorporated by reference into a Registration Statement or a
Prospectus after the initial filing of a Registration Statement, provide copies of such document to the Initial Purchasers on behalf of such Holders; and make representatives of the Company and the Subsidiary Guarantors as shall be reasonably
requested by the Holders of Transfer Restricted Notes, or the Initial Purchasers on behalf of such Holders, available for discussion of such document; and the Company and the Subsidiary Guarantors shall not, at any time after initial filing of a
Registration Statement, use or file any Prospectus, any amendment of or supplement to a Registration Statement, or any document that is to be incorporated by reference into a Registration Statement or a Prospectus, of which the Initial Purchasers
shall not have previously been advised and furnished a copy or to which the Initial Purchasers shall object; 
 (l) obtain a
CUSIP number for all Exchange Notes or Transfer Restricted Notes, as the case may be, not later than the effective date of a Registration Statement, and provide the Trustee with certificates for the Exchange Notes or the Transfer Restricted Notes,
as the case may be, in a form eligible for deposit with the Depositary; 
 (m) (i) in the case of a Shelf Registration, cause
the indenture to be qualified under the TIA in connection with the registration of the Transfer Restricted Notes, and, in the case of an Exchange Offer Registration, cause or maintain, as the case may be, the Indenture to be qualified under the TIA
in connection with the registration of the Exchange 

  

 -14- 

 
Notes, (ii) cooperate with the Trustee and the Holders to effect such changes to the Indenture as may be required for the Indenture to be, or continue
to be, so qualified in accordance with the terms of the TIA and (iii) execute, and use commercially reasonable efforts to cause the Trustee to execute, all documents as may be required to effect such changes, and all other forms and documents
required to be filed with the SEC to enable the Indenture to be so qualified in a timely manner; 
 (n) in the case of a Shelf
Registration, enter into agreements (including underwriting agreements) and take all other customary and appropriate actions in order to expedite or facilitate the disposition of such Transfer Restricted Notes and if so requested by the holders of
such Transfer Restricted Notes and in such connection whether or not an underwriting agreement is entered into and whether or not the registration is an underwritten registration: 
 (i) make such representations and warranties to the Holders of such Transfer Restricted Notes and the underwriters, if any, as the Company
and the Subsidiary Guarantors are able to make, in form, substance and scope as are customarily made by issuers to underwriters in similar underwritten offerings as may be reasonably requested by them; 
 (ii) in connection with an underwritten registration, obtain opinions of counsel to the Company and the Subsidiary Guarantors and updates
thereof (which counsel and opinions (in form, scope and substance) shall be reasonably satisfactory to the managing underwriters, if any, and the holders of a majority in principal amount of the Transfer Restricted Notes being sold) addressed to
each selling Holder and the underwriters, if any, covering the matters customarily covered in opinions requested in sales of securities or underwritten offerings and such other matters as may be reasonably requested by such Holders and underwriters;

 (iii) in connection with an underwritten registration, obtain “cold comfort” letters and updates thereof from the
Company’s and the Subsidiary Guarantor’s independent certified public accountants (and, if necessary, any other independent certified public accountants of any subsidiary of the Company or of any business acquired by the Company for which
financial statements are, or are required to be, included in the Registration Statement) addressed to the underwriters, if any, and use commercially reasonable efforts to have such letter addressed to the selling Holders of Transfer Restricted Notes
(to the extent consistent with Statement on Auditing Standards No. 72 of the American Institute of Certified Public Accountants), such letters to be in customary form and covering matters of the type customarily covered in “cold comfort”
letters to underwriters in connection with similar underwritten offerings; 
 (iv) enter into a securities sales agreement
with the Holders and an agent of the Holders providing for, among other things, the appointment of such agent for the selling Holders for the purpose of soliciting purchases of Transfer Restricted Notes, which agreement shall be in form, substance
and scope customary for similar offerings; 
  

 -15- 

 (v) if an underwriting agreement is entered into, cause the same to set forth
indemnification provisions and procedures substantially equivalent to the indemnification provisions and procedures set forth in Section 4 hereof with respect to the underwriters and all other parties to be indemnified pursuant to said
Section or, at the request of any underwriters, in the form customarily provided to such underwriters in similar types of transactions; and 
 (vi) deliver such documents and certificates as may be reasonably requested and as are customarily delivered in similar offerings to the Holders of a majority in principal amount of the Transfer Restricted Notes being
sold and the managing underwriters, if any. 
 The above shall be done at (i) the effectiveness of such Shelf Registration Statement (and
each post-effective amendment thereto) and (ii) each closing under any underwriting or similar agreement as and to the extent required thereunder; 
 (o) in the case of a Shelf Registration or if a Prospectus is required to be delivered by any Participating Broker-Dealer in the case of an Exchange Offer, make available for inspection by representatives of the
Holders of the Transfer Restricted Notes, any underwriters participating in any disposition pursuant to a Shelf Registration Statement, any Participating Broker-Dealer and any counsel or accountant retained by any of the foregoing, all
non-confidential financial and other records, pertinent corporate documents and properties of the Company or any Subsidiary Guarantor reasonably requested by any such persons, and cause the respective officers, directors, employees, and any other
agents of the Company and the Subsidiary Guarantors to supply all information reasonably requested by any such representative, underwriter, special counsel or accountant in connection with a Registration Statement, and make such representatives of
the Company and the Subsidiary Guarantors available for discussion of such documents as shall be reasonably requested by such persons; 
 (p) if so requested by the Initial Purchasers, in the case of an Exchange Offer Registration Statement, a reasonable time prior to filing of any Exchange Offer Registration Statement, any Prospectus forming a part
thereof, any amendment to an Exchange Offer Registration Statement or amendment or supplement to such Prospectus, provide copies of such document to the Initial Purchasers and to counsel to the Holders of Transfer Restricted Notes; and 

(q) in the case of a Shelf Registration, a reasonable time prior to filing any Shelf Registration Statement, any Prospectus forming a
part thereof, any amendment to such Shelf Registration Statement or amendment or supplement to such Prospectus, provide copies of such documents to the Initial Purchasers, if so requested, to the Holders of Transfer Restricted Notes to be covered
thereby, to counsel for such Holders designated by them and to the underwriter or underwriters of an underwritten offering of such Transfer Restricted Notes, if any, make such changes in any such document prior to the filing thereof relating to such
Holders or such Transfer Restricted Notes as the counsel to the Holders or the underwriter or underwriters reasonably request and not file any such document in a form to which the holders of a majority in aggregate principal amount of 

  

 -16- 

 
Transfer Restricted Notes covered by such Shelf Registration Statement, counsel for such Holders of the Transfer Restricted Notes covered by such Shelf
Registration Statement, or any underwriter shall not have previously been advised and furnished a copy of or to which the Majority Holders of Transfer Restricted Notes covered by such Shelf Registration Statement, counsel to such Holders of Transfer
Restricted Notes or any underwriter shall reasonably object, and make the representatives of the Company and the Subsidiary Guarantors available for discussion of such document as shall be reasonably requested by such Holders of Transfer Restricted
Notes, the counsel for such Holders of Transfer Restricted Notes or any underwriter; 
 (r) in the case of a Shelf
Registration, use commercially reasonable efforts to cause all Transfer Restricted Notes to be listed on any securities exchange on which similar debt securities issued by the Company and the Subsidiary Guarantors are then listed if requested by the
Holders of a majority in aggregate principal amount of such Transfer Restricted Notes covered by such Shelf Registration Statement, or if requested by the underwriter or underwriters of an underwritten offering of Transfer Restricted Notes, if any;

 (s) in the case of a Shelf Registration, use commercially reasonable efforts to cause the Transfer Restricted Notes to be
rated by the appropriate rating agencies, if so requested by the Holders of a majority in aggregate principal amount of the Transfer Restricted Notes covered by such Shelf Registration Statement, or if requested by the underwriter or underwriters of
an underwritten offering of Transfer Restricted Notes, if any; 
 (t) otherwise comply with all applicable rules and
regulations of the SEC and make available to their security holders, as soon as reasonably practicable after the effective date of the applicable Registration Statement, an earnings statement covering at least 12 months which shall satisfy the
provisions of Section 11(a) of the 1933 Act and Rule 158 thereunder; 
 (u) cooperate and assist in any filings required
to be made with FINRA and, in the case of a Shelf Registration, in the performance of any due diligence investigation by any underwriter and its counsel (including any “qualified independent underwriter” that is required to be retained in
accordance with the rules and regulations of FINRA); 
 (v) if reasonably requested by any Holder of Transfer Restricted Notes
covered by a Shelf Registration Statement, promptly include in a Prospectus supplement or post-effective amendment such information with respect to such Holder as such Holder reasonably requests to be included therein and make all required filings
of such Prospectus supplement or such post-effective amendment as soon as the Company has received notification of the matters to be so included in such filing; 
 (w) so long as any Transfer Restricted Notes remain outstanding, cause each Additional Guarantor upon such Person becoming an Additional
Guarantor, to execute a joinder to this Agreement; and 
 (x) amend or supplement the Prospectus contained in the Exchange
Offer Registration Statement for a period of up to 90 days after the last Exchange Date (as such 

  

 -17- 

 
period may be extended pursuant to this Agreement), in order to expedite or facilitate the disposition of any Exchange Notes by Participating Broker-Dealers
consistent with the positions of the staff of the SEC. The Company and the Subsidiary Guarantors agree that Participating Broker-Dealers shall be authorized to deliver such Prospectus (or, to the extent permitted by law, make available) during such
period in connection with the resales contemplated by this clause (x). 
 In the case of a Shelf Registration Statement, the Company
and the Subsidiary Guarantors may (as a condition to such Holder’s participation in the Shelf Registration) require each Holder of Transfer Restricted Notes to furnish to the Company and Subsidiary Guarantors such information regarding the
Holder and the proposed distribution by such Holder of such Transfer Restricted Notes as the Company and Subsidiary Guarantors may from time to time reasonably request in writing. 
 In the case of a Shelf Registration Statement, each Holder agrees that, upon receipt of any notice from the Company or any Subsidiary Guarantor of the
happening of any event or the discovery of any facts, each of the kind described in Section 3(e)(iii) or (vi) hereof, such Holder will forthwith discontinue disposition of Transfer Restricted Notes pursuant to a Registration
Statement until such Holder’s receipt of the copies of the supplemented or amended Prospectus contemplated by Section 3(k) hereof, and, if so directed by the Company and Subsidiary Guarantors, such Holder will deliver to the Company
and Subsidiary Guarantors (at its expense) all copies in such Holder’s possession, other than permanent file copies then in such Holder’s possession, of the Prospectus covering such Transfer Restricted Notes current at the time of receipt
of such notice. 
 If any of the Transfer Restricted Notes covered by any Shelf Registration Statement are to be sold in an underwritten
offering, the underwriter or underwriters and manager or managers that will manage such offering will be selected by the Majority Holders of such Transfer Restricted Notes to be included in such offering and shall be acceptable to the Company and
Subsidiary Guarantors. No Holder of Transfer Restricted Notes may participate in any underwritten registration hereunder unless such Holder (a) agrees to sell such Holder’s Transfer Restricted Notes on the basis provided in any
underwriting arrangements approved by the persons entitled hereunder to approve such arrangements and (b) completes and executes all questionnaires, powers of attorney, indemnities, underwriting agreements and other documents required under the
terms of such underwriting arrangements. 
 If the Company and the Subsidiary Guarantors shall give any notice to suspend the disposition of
Transfer Restricted Notes pursuant to a Registration Statement, the Company and the Subsidiary Guarantors shall extend the period during which such Registration Statement shall be maintained effective pursuant to this Agreement by the number of days
during the period from and including the date of the giving of such notice to and including the date when the Holders of such Transfer Restricted Notes shall have received copies of the supplemented or amended Prospectus necessary to resume such
dispositions. The Company and the Subsidiary Guarantors may suspend the disposition of Transfers Restricted Notes no more than an aggregate of 90 days in any 365-day period. 
  

 -18- 

 4. Indemnification; Contribution. 
 (a) The Company and the Subsidiary Guarantors agree to indemnify, jointly and severally, and hold harmless the Initial Purchasers and each
of their affiliates and any other Person under common control with the Initial Purchasers, each Holder, each Participating Broker-Dealer, each Person who participates as an underwriter (any such Person being an “Underwriter”) and
each Person, if any, who controls any Holder or Underwriter within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act (collectively the “Company Indemnitees”) as follows: 
 (i) against any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any untrue statement or alleged
untrue statement of a material fact contained in any Registration Statement (or any amendment or supplement thereto) pursuant to which Exchange Notes or Transfer Restricted Notes were registered under the 1933 Act, including all documents
incorporated therein by reference, any Free Writing Prospectus used in violation of this Agreement or any “issuer information” (“Issuer Information”) filed or required to be filed pursuant to Rule 433(d) under the 1933
Act, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading, or arising out of any untrue statement or alleged untrue statement of a material fact
contained in any Prospectus (or any amendment or supplement thereto) or the omission or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading; 
 (ii) against any and all loss, liability, claim, damage and expense whatsoever, as incurred, to the extent
of the aggregate amount paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim whatsoever based upon any such untrue statement or omission, or any such
alleged untrue statement or omission; provided that (subject to Section 4(d) below) any such settlement is effected with the written consent of the Company and the Subsidiary Guarantors; and 
 (iii) against any and all expense whatsoever, as incurred (including the fees and disbursements of counsel chosen by any indemnified
party), reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue statement
or omission, or any such alleged untrue statement or omission, to the extent that any such expense is not paid under subparagraph for (ii) above; 
 provided, however, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue statement or omission or alleged untrue statement or omission made in
reliance upon and in conformity with written information concerning any Company Indemnitee furnished to the Company by any Company Indemnitee expressly for use in a Registration Statement (or any amendment thereto) or any Prospectus (or any
amendment or supplement thereto); and provided, further, that the indemnity agreement contained in this subsection shall not inure to the benefit of any Company Indemnitee from whom 

  

 -19- 

 
the person asserting any such losses, claims, damages or liabilities purchased the Notes concerned, to the extent that a prospectus relating to such Notes
was required to be delivered by such Company Indemnitee in connection with such purchase and any such loss, claim, damage or liability of such Company Indemnitee results from the fact that there was not sent or given to such person, at or prior to
the sale of such Notes to such person, a copy of such prospectus if the Company had previously furnished copies thereof to such Company Indemnitee. 
 (b) Each Company Indemnitee, severally, but not jointly, agrees to indemnify and hold harmless the Company, the Subsidiary Guarantors, each Underwriter and the other selling Holders, and each of their respective directors and officers, and
each Person, if any, who controls the Company, any Subsidiary Guarantor, any Underwriter or any other selling Holder within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act, against any and all loss, liability,
claim, damage and expense described in the indemnity contained in Section 4(a) hereof, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in the Shelf Registration
Statement (or any amendment thereto) or any Prospectus included therein (or any amendment or supplement thereto) in reliance upon and in conformity with written information with respect to such Company Indemnitee furnished to the Company and the
Subsidiary Guarantors by such Company Indemnitee expressly for use in the Shelf Registration Statement (or any amendment thereto) or such Prospectus (or any amendment or supplement thereto); provided, however, that no such Company
Indemnitee shall be liable for any claims hereunder in excess of the amount of net proceeds received by such Company Indemnitee from the sale of Transfer Restricted Notes pursuant to such Shelf Registration Statement. 
 (c) Each indemnified party shall give notice as promptly as reasonably practicable to each indemnifying party of any action or proceeding commenced
against it in respect of which indemnity may be sought hereunder, but failure so to notify an indemnifying party shall not relieve such indemnifying party from any liability hereunder to the extent it is not materially prejudiced as a result thereof
and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity agreement. An indemnifying party may participate at its own expense in the defense of such action; provided,
however, that counsel to the indemnifying party shall not (except with the consent of the indemnified party) also be counsel to the indemnified party. In no event shall the indemnifying party or parties be liable for the fees and expenses of
more than one counsel (in addition to any local counsel) separate from their own counsel for all indemnified parties in connection with any one action or separate but similar or related actions in the same jurisdiction arising out of the same
general allegations or circumstances. No indemnifying party shall, without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of any judgment with respect to any litigation, or any investigation or
proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever in respect of which indemnification or contribution could be sought under this Section 4 (whether or not the indemnified parties are actual
or potential parties thereto), unless such settlement, compromise or consent (i) includes an unconditional release of each indemnified party from all liability arising out of such litigation, investigation, proceeding or claim and
(ii) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party. 
  

 -20- 

 (d) If the indemnification provided for in this Section 4, is for any reason unavailable to
or insufficient to hold harmless an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount of such losses, liabilities, claims,
damages and expenses incurred by such indemnified party, as incurred, in such proportion as is appropriate to reflect the relative fault of the Company and the Subsidiary Guarantors, on the one hand, and the Company Indemnitees, on the other hand,
in connection with the statements or omissions which resulted in such losses, liabilities, claims, damages or expenses, as well as any other relevant equitable considerations. 
 The relative fault of the Company and the Subsidiary Guarantors on the one hand and the Company Indemnitees on the other hand shall be determined by
reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company, the Subsidiary Guarantors or the
Company Indemnitees and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. 
 The Company, the Subsidiary Guarantors and the Company Indemnitees agree that it would not be just and equitable if contribution pursuant to this Section 4 were determined by pro rata allocation (even if
the Initial Purchasers were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to above in this Section 4. The aggregate amount of losses,
liabilities, claims, damages and expenses incurred by an indemnified party and referred to above in this Section 4 shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in investigating,
preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue or alleged untrue statement or omission or alleged
omission. 
 No Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the 1933 Act) shall be entitled to
contribution from any Person who was not guilty of such fraudulent misrepresentation. 
 For purposes of this Section 4, each
Person, if any, who controls an Initial Purchaser or Holder within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act shall have the same rights to contribution as such Initial Purchaser or Holder, and each director of
the Company or any Subsidiary Guarantor, and each Person, if any, who controls the Company or any Subsidiary Guarantor within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act shall have the same rights to
contribution as the Company and the Subsidiary Guarantors. The Initial Purchasers’ respective obligations to contribute pursuant to this Section 4 are several in proportion to the principal amount of Notes set forth opposite their
respective names in Schedule A to the Purchase Agreement and not joint. Notwithstanding the provisions of this Section 4, in no event shall a Holder be required to contribute any amount in excess of the amount by which the total price at
which all of the Notes sold by such Holder exceeds the amount of any damages that such Holder has otherwise been required to pay under Section 4(b) hereof. 
 The remedies provided for in this Section 4 are not exclusive and shall not limit any rights or remedies that may otherwise be available to any indemnified party at law or in equity. 
  

 -21- 

 The indemnity and contribution provisions contained in this Section 4 shall remain operative
and in full force and effect regardless of (i) any termination of this Agreement, (ii) any investigation made by or on behalf of the Company Indemnitees or any Person controlling any Company Indemnitee, or by or on behalf of the Company or
the Subsidiary Guarantors or the officers or directors of or any Person controlling the Company or the Subsidiary Guarantors, (iii) acceptance of any of the Exchange Notes and (iv) any sale of Transfer Restricted Notes pursuant to a Shelf
Registration Statement; provided, however, that the indemnity and contribution rights provided for, in this Section 4 shall not extend to any losses, liabilities or other damages arising out of actions occurring after the
termination of this Agreement. 
 5. Miscellaneous. 
 5.1 Rule 144 and Rule 144A. For so long as the Company and the Subsidiary Guarantors are subject to the reporting requirements of
Section 13 or 15 of the 1934 Act, the Company and the Subsidiary Guarantors covenant that they will file and furnish the reports required to be filed by them under the 1933 Act and Section 13(a) or 15(d) of the 1934 Act and the rules and
regulations adopted by the SEC thereunder. If the Company and the Subsidiary Guarantors cease to be so required to file and furnish such reports, the Company and Subsidiary Guarantors covenant that they will upon the request of any Holder of
Transfer Restricted Notes (a) make publicly available such information as is necessary to permit sales pursuant to Rule 144 under the 1933 Act, (b) deliver such information to a prospective purchaser as is necessary to permit sales
pursuant to Rule 144A under the 1933 Act and take such further action as any Holder of Transfer Restricted Notes may reasonably request, and (c) take such further action that is reasonable in the circumstances, in each case, to the extent
required from time to time to enable such Holder to sell its Transfer Restricted Notes without registration under the 1933 Act within the limitation of the exemptions provided by (i) Rule 144 under the 1933 Act, as such Rule may be amended from
time to time, (ii) Rule 144A under the 1933 Act, as such Rule may be amended from time to time, or (iii) any similar rules or regulations hereafter adopted by the SEC. Upon the request of any Holder of Transfer Restricted Notes, the
Company and the Subsidiary Guarantors will deliver to such Holder a written statement as to whether they have complied with such requirements. 
 5.2 No Inconsistent Agreements. The Company and the Subsidiary Guarantors have not entered into, and the Company and the Subsidiary Guarantors will not after the date of this Agreement enter into, any agreement which is
inconsistent with the rights granted to the Holders of Transfer Restricted Notes in this Agreement or otherwise conflicts with the provisions hereof. The rights granted to the Holders hereunder do not and will not for the term of this Agreement in
any way conflict with the rights granted to the holders of the Company’s or Subsidiary Guarantors’ other issued and outstanding securities under any such agreements. 
 5.3 Amendments and Waivers. The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified or
supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the Company and the Subsidiary Guarantors have obtained the written consent of Holders of at least a majority in aggregate principal amount of
the outstanding Transfer Restricted Notes affected by such amendment, modification, supplement, waiver or departure. 
  

 -22- 

 5.4 Notices. All notices and other communications provided for or permitted hereunder shall
be made in writing by hand delivery, registered first-class mail, telex, telecopier, or any courier guaranteeing overnight delivery (a) if to a Holder, at the most current address given by such Holder to the Company by means of a notice given
in accordance with the provisions of this Section 5.4, which address initially, and until so changed, is the address set forth in the Purchase Agreement with respect to the Initial Purchasers; and (b) if to the Company and the
Subsidiary Guarantors, initially at the Company’s address set forth in the Purchase Agreement, and thereafter at such other address of which notice is given in accordance with the provisions of this Section 5.4. 
 All such notices and communications shall be deemed to have been duly given: at the time delivered by hand, if personally delivered; three business days
after being deposited in the mail, postage prepaid, if mailed; when answered back, if telexed; when receipt is acknowledged, if telecopied; and on the next business day if timely delivered to an air courier guaranteeing overnight delivery.

 Copies of all such notices, demands, or other communications shall be concurrently delivered by the person giving the same to the Trustee
under the Indenture at the address specified therein. 
 5.5 Successor and Assigns. This Agreement shall inure to the benefit
of and be binding upon the successors, assigns and transferees of each of the parties, including, without limitation and without the need for an express assignment, subsequent Holders; provided that nothing herein shall be deemed to permit
any assignment, transfer or other disposition of Transfer Restricted Notes in violation of the terms of the Purchase Agreement or the Indenture. If any transferee of any Holder shall acquire Transfer Restricted Notes, in any manner, whether by
operation of law or otherwise, such Transfer Restricted Notes shall be held subject to all of the terms of this Agreement, and by taking and holding such Transfer Restricted Notes such person shall be conclusively deemed to have agreed to be bound
by and to perform all of the terms and provisions of this Agreement, including the restrictions on resale set forth in this Agreement and, if applicable, the Purchase Agreement, and such person shall be entitled to receive the benefits hereof. The
Initial Purchasers (in their capacity as Initial Purchasers) shall have no liability or obligation to the Company of the Subsidiary Guarantors with respect to any failure by a Holder to comply with, or any breach by any Holder of, any of the
obligations of such Holder under this Agreement 
 5.6 Third Party Beneficiaries. The Initial Purchasers (even if the Initial
Purchasers are not Holders of Transfer Restricted Notes) shall be third party beneficiaries to the agreements made hereunder between the Company and the Subsidiary Guarantors, on the one hand, and the Holders, on the other hand, and shall have the
right to enforce such agreements directly to the extent they deem such enforcement necessary or advisable to protect their rights or the rights of Holders hereunder. Each Holder of Transfer Restricted Notes shall be a third party beneficiary to the
agreements made hereunder between the Company and the Subsidiary Guarantors, on the one hand, and the Initial Purchasers, on the other hand, and shall have the right to enforce such agreements directly to the extent it deems such enforcement
necessary or advisable to protect its rights hereunder. 
  

 -23- 

 5.7 Remedies. Each of the Company and the Subsidiary Guarantors hereby agrees that monetary
damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Agreement and hereby agree to waive the defense in any action for specific performance that a remedy at law would be adequate.

 5.8 Counterparts. This Agreement may be executed in any number of counterparts and by the parties hereto in separate
counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. This Agreement may be executed by facsimile signature. 
 5.9 Headings. The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning
hereof. 
 5.10 Governing Law. This Agreement shall be governed by and construed in accordance with the law of the state of New
York without regard to the principles of conflict of laws thereof. 
 5.11 Severability. In the event that any one or more of
the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable, the validity, legality and enforceability of any such provision in every other respect and of the remaining provisions
contained herein shall not be affected or impaired thereby. 
 [signature page follows] 
  

 -24- 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	 FREEDOM GROUP, INC.,
 a Delaware corporation

		
	By:	 	 /s/ Stephen P. Jackson, Jr.

	Name:	 	Stephen P. Jackson, Jr.
	Title:	 	Chief Financial Officer

			
	GUARANTORS:
	
	RACI HOLDING, INC.
		
	By:	 	 /s/ Stephen P. Jackson, Jr.

	Name:	 	Stephen P. Jackson, Jr.
	Title:	 	Chief Financial Officer
	
	REMINGTON ARMS COMPANY, INC.
		
	By:	 	 /s/ Stephen P. Jackson, Jr.

	Name:	 	Stephen P. Jackson, Jr.
	Title:	 	Chief Financial Officer
	
	REMINGTON STEAM, LLC
		
	By:	 	 /s/ Julie Sears

	Name:	 	Julie Sears
	Title:	 	Manager
	
	RA BRANDS, L.L.C.
		
	By:	 	 /s/ Stephen P. Jackson, Jr.

	Name:	 	Stephen P. Jackson, Jr.
	Title:	 	Vice President
	
	THE MARLIN FIREARMS COMPANY
		
	By:	 	 /s/ Stephen P. Jackson, Jr.

	Name:	 	Stephen P. Jackson, Jr.
	Title:	 	Vice President
	
	H&R 1871, LLC
		
	By:	 	 /s/ Stephen P. Jackson, Jr.

	Name:	 	Stephen P. Jackson, Jr.
	Title:	 	Vice President

  

 -2- 

			
	DA ACQUISITIONS, LLC
		
	By:	 	 /s/ Stephen P. Jackson, Jr.

	Name:	 	Stephen P. Jackson, Jr.
	Title:	 	Chief Financial Officer
	
	BUSHMASTER HOLDINGS, LLC
		
	By:	 	 /s/ Stephen P. Jackson, Jr.

	Name:	 	Stephen P. Jackson, Jr.
	Title:	 	Treasurer
	
	BUSHMASTER FIREARMS INTERNATIONAL, LLC
		
	By:	 	 /s/ Paul A. Miller

	Name:	 	Paul A. Miller
	Title:	 	Vice President
	
	DPMS FIREARMS, LLC
		
	By:	 	 /s/ Paul A. Miller

	Name:	 	Paul A. Miller
	Title:	 	Vice President
	
	E-RPC, LLC
		
	By:	 	 /s/ Stephen P. Jackson, Jr.

	Name:	 	Stephen P. Jackson, Jr.
	Title:	 	Chief Financial Officer

  

 -3- 

			
	CONFIRMED AND ACCEPTED,
	as of the date first above written:
	
	BANC OF AMERICA SECURITIES LLC
		
	By:	 	 /s/ Edward F. Martin

	Name:	 	Edward F. Martin
	Title:	 	Vice President
	
	DEUTSCHE BANK SECURITIES INC.
		
	By:	 	 /s/ Keith Wargo

	Name:	 	Keith Wargo
	Title:	 	Managing Director
	
	DEUTSCHE BANK SECURITIES INC.
		
	By:	 	 /s/ Marco Habert

	Name:	 	Marco Habert
	Title:	 	Managing Director
	
	WELLS FARGO SECURITIES, LLC
		
	By:	 	 /s/ Stephen M. Neill

	Name:	 	Stephen M. Neill
	Title:	 	Managing Director

 For themselves and as representatives of the other Initial Purchasers 
  

 -4- 

 Schedule A 
  

					
		 	Initial Purchaser	 	
			
		 	Banc of America Securities LLC	 	
		 	Deutsche Bank Securities Inc.	 	
		 	Wells Fargo Securities LLC	 	
		 	Barclays Capital Inc.	 	
		 	Jefferies & Company, Inc.	 	

  

 -5-Cross License Agreement

 Exhibit 10.1 
 CROSS LICENSE AGREEMENT 
 This License Agreement (this “Agreement”) is made effective as of
June 30, 2009 (the “Effective Date”) by and among Alphatec Spine, Inc., a Delaware corporation with a principal place of business at 5818 El Camino Real, Carlsbad, California 92008 (“Alphatec”), International Spinal
Innovations, LLC, a limited liability company organized under the laws of the state of Connecticut, with an address at 97 Balfour Drive, West Hartford, CT 06117 (“ISI”), and, for purposes of Sections 4.1, 4.4, 7.3, and 11.15 hereof only,
Alphatec Holdings, Inc., a Delaware corporation with a principal place of business at 5818 El Camino Real, Carlsbad, California 92008 (“Holdings”). Alphatec and ISI are each hereafter referred to individually as a “Party” and
together as the “Parties”. 
 WHEREAS, ISI is the owner of, or otherwise controls, certain proprietary Licensed ISI Patents
(hereinafter defined); 
 WHEREAS, Alphatec is the owner of, or otherwise controls, certain proprietary Licensed Alphatec Patents
(hereinafter defined); 
 WHEREAS, Alphatec desires to obtain a license from ISI to the Licensed ISI Patents to develop and commercialize
Licensed Alphatec Products (hereinafter defined); 
 WHEREAS, ISI desires to obtain a license from Alphatec to the Licensed Alphatec Patents
to develop and commercialize Licensed ISI Products (hereinafter defined); and 
 WHEREAS, ISI and Alphatec each desire to cross-license the
other on the terms and subject to the conditions of this Agreement. 
 NOW, THEREFORE, in consideration of the mutual covenants contained
herein, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties hereby agree as follows: 
 1. DEFINITIONS 
 Whenever used in this Agreement with an initial capital letter, the terms defined in
this Article 1 shall have the meanings specified. 
 1.1 “Affiliate” shall mean any company, corporation,
partnership, limited liability company, trust, or other business entity that directly or indirectly controls, is controlled by, or is under common control with a designated person or entity, and for such purpose “control” shall mean the
possession, direct or indirect, of the power to direct or cause the direction of the management and policies of the entity, whether through the ownership of voting securities, by contract or otherwise. 
  

 1 
 Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately 
 with the Secretary of the
Commission pursuant to the Registrant’s application requesting 
 confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as 
 amended. 

 1.2 “Common Stock” shall mean the common stock of Holdings, which trades on
Nasdaq under the symbol ATEC and any securities into which such common stock may hereafter be reclassified, converted or exchanged. 
 1.3
“Confidential Information” shall mean with respect to a Party (the “Receiving Party”), all information which is disclosed by the other Party (the “Disclosing Party”) to the Receiving Party hereunder or to
any of its employees, consultants, Affiliates, licensees or sublicensees, except to the extent that the Receiving Party can demonstrate by written record or other suitable physical evidence that such information, (a) as of the date of
disclosure is known to the Receiving Party or its Affiliates other than by virtue of a prior confidential disclosure to the Receiving Party or its Affiliates; (b) as of the date of disclosure is in, or subsequently enters, the public domain,
through no fault or omission of the Receiving Party; (c) is obtained from a Third Party having a lawful right to make such disclosure free from any obligation of confidentiality to the Disclosing Party; or (d) is independently developed by
or for the Receiving Party without reference to or reliance upon any Confidential Information of the Disclosing Party. 
 1.4
“Guarantee and Agreement” shall mean the guarantee and agreement of Holdings set forth in Section 11.15 hereof. 
 1.5 “Alphatec Inventions” shall mean any enhancement, invention or discovery created or identified, owned or controlled by Alphatec that does not fall within the Licensed ISI Patents. Alphatec Inventions shall not
include any invention conceived in whole or in part before or after the Effective Date by ISI or any of its agents, employees, consultants, or representatives except as provided for in Section 3.1.1 of this Agreement. 
 1.6 “ISI Inventions” shall mean any enhancement, invention or discovery created or identified, owned or controlled by ISI that
does not fall within the Licensed Alphatec Patents. ISI Inventions shall not include any invention conceived in whole or in part before or after the Effective Date by Alphatec or any of its agents, employees, consultants (including when ISI acts as
a consultant for Alphatec) or representatives. 
 1.7 “ISI Indemnitees” and “Alphatec
Indemnitees” (each individually an “Indemnitee”) shall have the meaning given in Section 8.1. 
 1.8 “Licensed Field” shall mean [***]. 
 1.9 “Licensed ISI Patents” shall
mean the patents and patent applications described in Schedule A attached hereto, and all divisional, continuation, continuation-in-part (to the extent that the continuation-in-part is entitled to the priority date of an initial patent or
patent application which is the subject of this Agreement), reissue, reexamination, registration, renewal, or extension, or any patent issuing therefrom or any supplementary protection certificates related thereto, and all foreign counterparts to
any of the foregoing. 
  

 2 
 Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately 
 with the Secretary of the
Commission pursuant to the Registrant’s application requesting 
 confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as 
 amended. 

 1.10 “Licensed Alphatec Patents” shall mean the patents and patent applications
described in Schedule B attached hereto, and any divisional, continuation, continuation-in-part (to the extent that the continuation-in-part is entitled to the priority date of an initial patent or patent application which is the subject of
this Agreement), reissue, reexamination, registration, renewal, or extension, or any patent issuing therefrom or any supplementary protection certificates related thereto, and any foreign counterparts to any of the foregoing. 
 1.11 “Licensed Alphatec Product” shall mean any product sold by Alphatec, its affiliates, or Sublicensees that, absent the
license provided in this Agreement, would infringe a Valid Claim of the Licensed ISI Patents. 
 1.12 “Licensed ISI
Product” shall mean [***] made, used, offered for sale, or sold by ISI, its affiliates, or Sublicensees that, absent the license provided in this Agreement, would infringe a Valid Claim of the Licensed Alphatec Patents.

 1.13 “Net Sales” shall mean the gross amount invoiced or otherwise payable to Alphatec, its Affiliates, or
Sublicensees on account of sales or other transfers of a Licensed Alphatec Product anywhere in the Territory during a designated period, less (to the extent otherwise then or previously included in amounts invoiced for such Licensed Product and in
respect of which no previous deduction was taken): 
 1.13.1 trade, cash and quantity discounts or rebates actually allowed or taken on
Licensed Alphatec Products, including discounts or rebates to governmental or managed care organizations; 
 1.13.2 credits or allowances
actually given or made for rejection of, and for uncollectible amounts (except to the extent later collected) on, or return of previously sold Licensed Alphatec Products; 
 1.13.3 sales commissions paid to a Third-Party; 
 1.13.4 any charges for insurance, freight, and other transportation costs directly related to the delivery of Licensed Alphatec Product to the extent included in the gross invoiced sales price; 
 1.13.5 any tax, tariff, duty or governmental charge levied on the sales, transfer, transportation or delivery of a Licensed Alphatec Product (including
any tax such as a value added or similar tax or government charge), other than franchise or income tax of any kind whatsoever; and 
 1.13.6
any import or export duties or their equivalent borne. 
 In addition, should Alphatec be required, in order to lawfully exercise its rights as to a Licensed
Alphatec Product, to obtain additional rights in a country to patents of any Third Parties which are not Affiliates of Alphatec, which patents are (i) pending or 

  

 3 
 Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately 
 with the Secretary of the
Commission pursuant to the Registrant’s application requesting 
 confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as 
 amended. 

 
issued on the Effective Date, and (ii) required for Alphatec to practice the inventions described in the Licensed ISI Patents, then Alphatec may also
deduct from Net Sales with respect to a designated period the amount of the royalty Alphatec is required to pay to such Third Party or Parties for such necessary rights to such patents with respect to such Licensed Alphatec Product. 
 “Net Sales” shall not include amounts invoiced to or otherwise payable by Alphatec, any of its Affiliates and/or any Sublicensees for Licensed Alphatec
Products sold or otherwise transferred to Alphatec or any of its Affiliates and/or its Sublicensees, unless the Licensed Alphatec Product is consumed by the invoiced entity. 
 1.14 “Shares” shall have the meaning set forth in Paragraph 4.1.1(a) hereof. 
 1.15 “Alphatec Sublicensee” shall mean any Third Party to whom Alphatec grants a sublicense of some or all of the rights granted
to Alphatec under this Agreement. 
 1.16 “ISI Sublicensee” shall mean any Third Party to whom ISI grants a
sublicense of some or all of the rights granted to ISI under this Agreement. 
 1.17 “Technology” shall mean all of
the following intangible legal rights, whether or not filed, perfected, registered or recorded, applicable to the Licensed Field: (i) inventions, patents, patent disclosures, patent rights, including any and all continuations,
continuations-in-part, divisionals, reissues, re-examinations, utility models, industrial designs and design patents or any extensions thereof, (ii) rights associated with works of authorship, including without limitation, copyrights, copyright
applications and copyright registrations and (iii) any and all proprietary ideas, inventions, discoveries, Confidential Information, data, results, formulae, designs, specifications, methods, processes, techniques, ideas, know-how, technical
information (including, without limitation, structural and functional information), process information, pre-clinical information, clinical information, and any and all proprietary control and manufacturing data and materials, whether or not
patentable. 
 1.18 “Term” shall have the meaning given in Section 9.1. 
 1.19 “Territory” shall mean all countries and jurisdictions of the world. 
 1.20 “Third Party” shall mean any person or entity other than Alphatec, ISI and their respective Affiliates. 
 1.21 “Valid Claim” shall mean a claim indicated as allowable in an issued, unexpired patent or in a pending patent application
within the Licensed ISI Patents and Licensed Alphatec Patents that (a) has not been finally cancelled, withdrawn, abandoned or rejected by any administrative agency or other body of competent jurisdiction, (b) has not been revoked, held
invalid, or declared unpatentable or unenforceable in a decision of a court or other body of competent jurisdiction that is unappealable or unappealed within the time allowed for appeal, (c) has not been rendered unenforceable through
disclaimer or otherwise, and (d) is not lost through interference proceedings. 
  

 4 
 Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately 
 with the Secretary of the
Commission pursuant to the Registrant’s application requesting 
 confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as 
 amended. 

 1.22 “First Commercial Sale” shall mean the date of the first transaction,
transfer or disposition for value by or on behalf of Alphatec or any Affiliate or Sublicensee of Alphatec to a Third Party of a Licensed Alphatec Product. 
 2. GRANT OF RIGHTS 
 2.1 License Grant to Alphatec. 
 2.1.1 ISI Grant of License to Alphatec. ISI hereby grants to Alphatec an exclusive (even as to ISI, but subject to the limitations set forth in
Subsection 2.1.2) royalty-bearing license, including the right to grant sublicenses, to the Licensed ISI Patents to make, have made, import, export, use, offer for sale or sell Licensed Alphatec Products in the Territory, and to conduct research and
development in support of the aforementioned licensed uses, in all cases, subject to the terms and conditions of this Agreement. The license granted in this subsection shall entitle Alphatec to sell and market Licensed Alphatec Products through
Third-Party distributors. 
 2.1.2 Limitation of ISI’s License Grant to Alphatec. With respect to any laterally delivered
multi-shaft interbody implant, ISI’s license grant to Alphatec in Subsection 2.1.1 is non-exclusive, and shall only be sublicensable in accordance with Subsection 6.2. 
 2.2 License Grant to ISI. Alphatec hereby grants to ISI a non-exclusive, fully-paid, royalty-free license including the right to grant
sublicenses, provided that such sublicense shall only be granted in accordance with Subsection 6.2, to the Licensed Alphatec Patents to make, have made, import, export, use, offer for sale or sell a Licensed ISI Product in the Territory, and to
conduct research and development in support of the aforementioned licensed uses, in all cases, subject to the terms and conditions of this Agreement. The license granted in this subsection shall entitle ISI to sell and market ISI Products through
Third-Party distributors. 
 3. DEVELOPMENT AND COMMERCIALIZATION OF LICENSED ALPHATEC PRODUCTS. 
 3.1 Commercialization. 
 3.1.1
Responsibility. From and after the Effective Date, Alphatec shall have full control and authority over the development and commercialization of Licensed Alphatec Products in the Licensed Field in the Territory. Alphatec shall own all Alphatec
Inventions. Alphatec shall own all Technology resulting from (i) the joint efforts of the agents, Affiliates and employees of ISI and Alphatec during the term of this Agreement, or (ii) any efforts performed by ISI pursuant to
Section 3.2. 
  

 5 
 Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately 
 with the Secretary of the
Commission pursuant to the Registrant’s application requesting 
 confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as 
 amended. 

 3.1.2 Diligence. After the Effective Date, Alphatec will exercise commercially reasonable efforts
to develop a Licensed Alphatec Product, such commercially reasonable efforts to take into account the competitiveness of the marketplace, the proprietary position of the Licensed Alphatec Product, the relative potential safety and efficacy of the
Licensed Alphatec Product, the cost of goods and availability of capacity to manufacture and supply the Licensed Alphatec Product at commercial scale, the profitability of the applicable Licensed Alphatec Product, and other relevant factors
including, without limitation, technical, legal, scientific or medical factors. 
 3.2 ISI Assistance. ISI shall transfer to
Alphatec all drawings, prototypes and other related materials in its possession or control as of the Effective Date that relate to a single-shaft Licensed Alphatec Product (the “Prototype Transfer”). As consideration for the Prototype
Transfer, within ten (10) business days of the receipt of an invoice from ISI, Alphatec shall reimburse ISI for all expenses incurred as of the Effective Date in connection with the creation of the materials that are the subject of the
Prototype Transfer; provided that such payment shall not exceed [***]. In addition, upon Alphatec’s reasonable request, ISI will provide commercially reasonable assistance to develop Alphatec’s first Licensed Alphatec Product.
Alphatec will pay ISI for such assistance [***] plus reasonable travel and out-of-pocket expenses. 
 4. PAYMENTS AND ROYALTIES

 4.1 Initial Payment; Milestone Payments; Royalty Payments; Royalty Rates; and Minimum Quarterly Royalty. 
 4.1.1 Initial Payment Upon the terms and subject to the conditions contained herein, Alphatec shall issue and transfer with full title guaranteed,
two hundred sixty thousand (260,000) shares (the “Shares”) of Common Stock (the “Share Payment”). ISI’s license grant to Alphatec constitutes full consideration for the Share Payment. The Share Payment shall be due and
payable within twenty (20) business days of the Effective Date. The payment described in this Subsection 4.1.1 shall not be credited against or otherwise reduce any other amounts payable hereunder. 
 4.1.2 Milestone Payments. Alphatec shall pay milestone payments to ISI (each such payment a “Milestone Payment”) as specified below no
more than thirty (30) days after the occurrence of the corresponding event designated below, unless this Agreement has been terminated prior to such due date. No Milestone Payments described in this Subsection 4.1.2 shall be credited against or
otherwise reduce any other amounts payable hereunder. 
  

			
	 Event
	 	 Milestone Payment

	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]

  

 6 
 Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately 
 with the Secretary of the
Commission pursuant to the Registrant’s application requesting 
 confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as 
 amended. 

 4.1.3 Royalty Payments. During the Term of this Agreement, Alphatec shall pay to ISI within
thirty (30) days of the end of each calendar quarter royalties of [***] of Net Sales of Licensed Alphatec Products. Only one royalty shall be payable to ISI pursuant to this Section 4.1.3 for each sale of a Licensed Alphatec
Product, notwithstanding that more than one patent or patent claim reads upon such Licensed Alphatec Product. 
 4.1.4 Minimum Royalty
Payment. In accordance with the chart set forth in this Subsection 4.1.4, Alphatec shall pay ISI a minimum annual royalty amount. No minimum annual royalty described in this Subsection 4.1.4 shall be credited against or otherwise reduce any
other amounts payable hereunder. For a particular year, in the event that the sum of the earned royalties on Net Sales paid pursuant to Subsection 4.1.3 above with respect to such calendar is less than the minimum annual royalty for such year
designated below, the obligation to pay the difference to ISI shall accrue on the last day of such year and be payable by Alphatec no later than forty-five (45) days following the end of such year: 
  

			
	 Twelve (12) Months Ending
	 	 Minimum Annual Royalty

	[***]	 	[***]

 4.2 Payment, Conversion and Withholding. 
 4.2.1 Payment. All payments hereunder shall originate in the United States and be made in United States dollars. 
 4.2.2 Conversion. Conversion of foreign currency to United States dollars shall be made at the conversion rate existing in the United States (as
reported in The Wall Street Journal) on the last business day of the quarter immediately preceding the applicable calendar quarter. If The Wall Street Journal ceases to be published, then the rate of exchange to be used shall be that
reported in such other business publication of national circulation in the United States as the Parties reasonably agree.  
 4.2.3
Tax Withholding; Restrictions on Payment. All taxes, assessments and fees of any nature levied or incurred on account of any payments from Alphatec to ISI accruing under this Agreement, by national, state or local governments, will be assumed
and paid by Alphatec, except taxes levied thereon as income to ISI and if such taxes are required by applicable law to be withheld by Alphatec they will be deducted from payments due to ISI and will be timely paid by Alphatec to the proper taxing
authority for the account of ISI, a receipt or other proof of payment therefore secured and sent to ISI as soon as practicable. Alphatec shall remit all payments to ISI hereunder from within the United States. 
  

 7 
 Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately 
 with the Secretary of the
Commission pursuant to the Registrant’s application requesting 
 confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as 
 amended. 

 4.3 Records Retention; Review. 
 4.3.1 Record Retention. Alphatec shall keep accurate books and accounts of the computation of the number of Licensed Alphatec Products sold and
the Net Sales of Alphatec, its Affiliates and Sublicensees of Licensed Alphatec Products, and shall cause such Affiliates and Sublicensees to keep such records of their respective sales of Licensed Alphatec Products and Net Sales of Licensed
Alphatec Products, in sufficient detail to permit accurate determination of all figures necessary for verification of payments required to be paid hereunder, which books and accounts shall be maintained for at least three (3) years from the end
of the calendar year to which they pertain. 
 4.3.2 Review. At the request of ISI, which shall not be made more frequently than once
per calendar year during the Term, on a business day designated by ISI upon at least thirty (30) days’ prior written notice to Alphatec, Alphatec shall permit, under confidentiality obligations with terms substantially the same as those
hereunder, an independent certified public accountant reasonably selected by ISI and reasonably acceptable to Alphatec to inspect (during regular business hours) the relevant records required to be maintained by Alphatec under Subsection 4.3.1.
In the event such inspection reveals an underpayment, such underpayment shall be due and payable by Alphatec within thirty (30) days of the date of such inspection, together with interest thereon from the date the amount due but unpaid was
first due until the date paid, at the lower of [***] per annum or the maximum rate permitted by applicable law. Such inspection shall be at the expense of ISI unless there is an underpayment that differs by greater than [***] from the amount that
was otherwise due, in which event Alphatec shall pay the reasonable costs of the inspection. The foregoing is without prejudice to the right of Alphatec to dispute the conclusion of the accountant, but such dispute shall not relieve Alphatec of its
obligation to pay interest and, under the circumstances described, costs of inspection as to amount actually due. 
 4.4 Matters
Related to the Issuance of Common Stock. 
 4.4.1 Representations, Warranties and Certain Covenants of Alphatec and of
Holdings. Alphatec and Holdings, each separately and jointly represent, warrant, and covenant that: 
 (a) Assuming the covenant of ISI
contained in Subsection 4.4.2 of this Agreement is complied with, the issuance to ISI of each Share will be in compliance with all applicable federal and state securities laws in connection with the offer, issuance and sale of the securities.

 (b) The execution, delivery and performance of this Agreement by Holdings, the issuance and sale of the Shares and the consummation by
Holdings of the other transactions by it contemplated hereby do not and will not on the date of the 

  

 8 
 Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately 
 with the Secretary of the
Commission pursuant to the Registrant’s application requesting 
 confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as 
 amended. 

 
issuance and sale of the Shares (i) conflict with or violate any provision of Holdings’ or any of its subsidiaries certificates or articles of
incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any lien or
encumbrance upon any of the properties or assets of Holdings or any of its subsidiaries, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit
facility, debt or other instrument or other understanding to which Holdings or any of its subsidiaries is a party or by which any property or asset of Holdings or any such subsidiary is bound or affected, in each case with respect to this Subsection
(ii), to a degree that would have a material adverse effect on the assets or results of operations of Holdings or its subsidiaries when considered as a whole (a “Material Adverse Effect”), or (iii) conflict with or result in a
violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which Holdings or any such subsidiary is subject (including federal and state securities laws and
regulations), or by which any property or asset of Holdings or any such subsidiary is bound or affected, in each case with respect to this Subsection (iii), to a degree that would have a Material Adverse Effect. 
 (c) Prior to the issuance of the Shares, Holdings shall obtain all consents, approvals, orders, authorizations or registrations, qualifications,
designations, declarations, and make all filings or registrations with any court or other federal, state, local or other governmental authority or other person that is required in order to issue the Shares. 
 (d) The Shares, when issued in accordance herewith, will be (i) duly authorized, (ii) duly and validly issued, (iii) fully paid and
nonassessable, and (iv) free and clear of all liens or encumbrances imposed by Holdings, other than restrictions on transfer provided for herein. 
 (e) At all times prior to the second anniversary of the last issuance of the Shares during which there are Shares outstanding which have not been previously (i) sold or transferred to or through a broker or
dealer or underwriter in a public distribution, or (ii) sold or transferred in a transaction exempt from the registration and prospectus delivery requirements of the Securities Act of 1933, as amended (the “Securities Act”), in the
case of either Subsection (i) or Subsection (ii) in such a manner that, upon the consummation of such sale or transfer, all transfer restrictions and restrictive legends with respect to such Shares upon the consummation of such sale or
transfer and Holdings shall use its commercially reasonable efforts to: (1) comply with the requirements of Rule 144(c) under the Securities Act with respect to current public information about Holdings, and (2) furnish to ISI such
non-publicly available reports and documents of Holdings as ISI may reasonably request to avail itself of Rule 144 of the Securities Act, or any similar rule or regulation of the United States Securities Exchange Commission allowing ISI to sell the
Shares without registration. 
 4.4.2 Representations and Warranties of ISI. ISI represents and warrants that (i) it is an
“accredited investor” as that term is defined in Rule 501(a) of Regulation D of the Securities Act; (ii) it is acquiring the Shares for investment for ISI’s own 

  

 9 
 Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately 
 with the Secretary of the
Commission pursuant to the Registrant’s application requesting 
 confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as 
 amended. 

 
account and not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, without prejudice, however, to ISI’s right
to at all times to sell or otherwise dispose of any or all of the Shares so issued in compliance with applicable federal and state securities laws and (iii) it does not have any contract, undertaking, agreement or arrangement with any person to
sell, transfer or grant participation to such person or to any third person, with respect to any of such Shares. 
 4.4.3 Restrictions on
the Shares. ISI understands and agrees that the Shares may not be sold, transferred, or otherwise disposed of without registration under the Securities Act or an exemption therefrom, and that in the absence of an effective registration statement
covering the Shares or any available exemption from registration under the Securities Act, the Shares must be held indefinitely. ISI agrees and acknowledges that the following legend will be placed on the back of any certificate evidencing the
Shares: 
 “THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE
SOLD, TRANSFERRED, ASSIGNED OR HYPOTHECATED UNLESS THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT COVERING SUCH SECURITIES, THE SALE IS MADE IN ACCORDANCE WITH RULE 144 UNDER THE ACT, OR THE CORPORATION RECEIVES AN OPINION OF COUNSEL
FOR THE HOLDER OF THESE SECURITIES REASONABLY SATISFACTORY TO THE CORPORATION, STATING THAT SUCH SALE, TRANSFER, ASSIGNMENT OR HYPOTHECATION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SUCH ACT.” 
 4.4.4 Limitation on the Number of Shares Issued. Notwithstanding anything to the contrary in this Agreement, in no event shall the aggregate
number of Shares issued pursuant to this Agreement be greater than nine and ninety-nine one-hundredths percent (9.99%) of the number of shares of Common Stock outstanding on the Effective Date. In the event that an issuance of Shares pursuant
to this Agreement would cause an aggregate issuance of Shares that is more than nine and ninety-nine one-hundreths percent (9.99%) of the number of shares Common Stock outstanding on the Effective Date, Alphatec shall make a cash payment to ISI
equal to the difference between cash value of the Shares that were scheduled to be issued pursuant to this Agreement, and the value of the Shares that were actually issued after giving effect to the limitation set forth in this Section 4.4.4.

  

 10 
 Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately 
 with the Secretary of the
Commission pursuant to the Registrant’s application requesting 
 confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as 
 amended. 

 5. TREATMENT OF CONFIDENTIAL INFORMATION 
 5.1 Confidential Obligations. ISI and Alphatec each recognize that the other Party’s Confidential Information constitutes highly
valuable and proprietary confidential information. ISI and Alphatec each agree that during the Term and for [***] thereafter, it will keep confidential, and will cause its employees, consultants, Affiliates and sublicensees to keep
confidential, all Confidential Information of the other Party. Neither ISI nor Alphatec nor any of their respective employees, consultants, Affiliates or Sublicensees shall use Confidential Information of the other Party for any purpose whatsoever
other than exercising any rights granted to it or reserved by it hereunder. Without limiting the foregoing, each Party may disclose information to the extent such disclosure is reasonably necessary to (a) file, prosecute or defend litigation in
accordance with the provisions of this Agreement or (b) comply with applicable laws, regulations (including those of the United States Securities Exchange Commission) or court orders; provided, however, that if a Party is required to make any
such disclosure of the other Party’s Confidential Information in connection with any of the foregoing, it will give reasonable advance notice to the other Party of such disclosure requirement and will use reasonable efforts to cooperate with
such other Party in efforts to secure confidential treatment of such information required to be disclosed. 
 5.2 Limited Disclosure
and Use. ISI and Alphatec each agree that any disclosure of the other Party’s Confidential Information to any officer, employee, consultant or agent of the other Party or any of its Affiliates or Sublicensees shall be made only if and
to the extent necessary to carry out its rights and responsibilities under this Agreement, shall be limited to the maximum extent possible consistent with such rights and responsibilities and shall only be made to the extent any such persons are
bound by written confidentiality obligations to maintain the confidentiality thereof and not to use such Confidential Information except as expressly permitted by this Agreement. ISI and Alphatec each further agree not to disclose or transfer the
other Party’s Confidential Information to any Third Parties under any circumstance without the prior written approval from the other Party (such approval not to be unreasonably withheld), except as otherwise required by law, and except as
otherwise expressly permitted by this Agreement. Each Party shall take such action, and shall cause its Affiliates or Sublicensees to take such action, to preserve the confidentiality of each other’s Confidential Information as it would
customarily take to preserve the confidentiality of its own Confidential Information, using, in all such circumstances, not less than reasonable care. Each Party, upon the request of the other Party, will return all the Confidential Information
disclosed or transferred to it by the other Party pursuant to this Agreement, including all copies and extracts of documents and all manifestations in whatever form, within sixty (60) days of such request or, if earlier, the termination or
expiration of this Agreement; provided however, that a Party may retain (i) any Confidential Information of the other Party relating to any license which expressly survives such termination, and (ii) one (1) copy of all other
Confidential Information in inactive archives in legal counsel’s files solely for the purpose of establishing the contents thereof. 
 5.3 Publicity. Neither Party may publicly disclose the existence or terms or any other matter of fact regarding this Agreement without the prior written consent of the other Party, which consent shall not be unreasonably
withheld or delayed; 

  

 11 
 Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately 
 with the Secretary of the
Commission pursuant to the Registrant’s application requesting 
 confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as 
 amended. 

 
provided, however, that either Party may make such a disclosure (i) to the extent required by law or by the requirements of any nationally recognized
securities exchange, quotation system or over-the-counter market on which such Party has its securities listed or traded, or (ii) to any prospective Sublicensees, or to investors, prospective investors, lenders and other potential financing
sources, who are obligated to keep such information confidential. The Parties, upon the execution of this Agreement, will mutually agree to a press release with respect to this transaction for publication. Once such press release or any other
written statement is approved for disclosure by both Parties, neither Party may make subsequent public disclosure of the contents of such statement without the further approval of the other Party. 
 5.4 Use of Name. Neither Party shall employ or use the name of the other Party in any promotional materials or advertising without the
prior express written permission of the other Party. 
 6. PROVISIONS CONCERNING THE FILING, PROSECUTION, AND MAINTENANCE OF PATENT RIGHTS

 6.1 Certain Patent Filing, Prosecution and Maintenance. With respect to any Licensed ISI Patents and Licensed Alphatec
Patents, Alphatec shall be responsible for and shall use reasonably efforts in preparing, filing, prosecuting, obtaining, and maintaining all Licensed ISI Patents and Licensed Alphatec Patents in the countries of its choosing in the Territory using
patent counsel chosen by Alphatec. The related costs shall be borne entirely by Alphatec. ISI shall provide reasonable assistance to Alphatec with respect to the prosecution of each patent application of the Licensed ISI Patents. ISI agrees to send
Alphatec copies of all file histories and prosecution documents for each of the patent applications of the Licensed ISI Patents, within thirty (30) days of receipt by ISI. ISI shall have the right, but not the obligation, to assume
responsibility for any Licensed ISI Patents that Alphatec intends to abandon or otherwise cause or allow to be forfeited. Alphatec shall give ISI at least sixty (60) days written notice prior to abandonment or other forfeiture of any Licensed
ISI Patents or any part of the Licensed ISI Patents so as to permit ISI to exercise its rights under this Subsection 6.1. 
 6.2 Notice
of Infringement. If, during the Term, either Party learns of any actual, alleged or threatened infringement by a Third Party of any Licensed ISI Patents or Licensed Alphatec Patents under this Agreement, such Party shall promptly notify the
other Party and shall provide such other Party with available evidence of such infringement. Following the delivery of such notice of infringement, neither Party shall be entitled to enter into a sublicense with the Third-Party infringer with
respect to any non-exclusive rights that have been granted to such Party in accordance with this Agreement, unless such sublicense was granted in accordance with Subsection 6.3. 
 6.3 Infringement of Licensed Patents. With respect to any notice of a Third Party infringement of the Licensed ISI Patents or Licensed
Alphatec Patents, the Parties shall meet as soon as reasonably practicable to discuss such infringement and 

  

 12 
 Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately 
 with the Secretary of the
Commission pursuant to the Registrant’s application requesting 
 confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as 
 amended. 

 
determine an appropriate course of action. The Parties jointly shall appoint one of the Parties as the “Leading Party” to bring an action
against such Third Party infringer or otherwise address such alleged infringement within sixty (60) days from the date of notice and to control such litigation or other means of addressing such infringement as follows: 
 6.3.1 In the event that the Third Party is believed to solely infringe the non-exclusive rights granted by ISI to Alphatec under this Agreement, then
ISI shall have the first option to be the Leading Party. In all other situations, Alphatec shall have the first option to be the Leading Party. 
 6.3.2 If a Party with the option to be the Leading Party declines such option, the other Party shall have the option to become the Leading Party. 
 The Party that is the non-Leading Party shall cooperate with the Leading Party in any such suit brought by the Leading Party, and shall have the right to consult with the Leading Party and participate in and be represented by independent
counsel in such litigation at its own expense. If a non-Leading Party elects not to be represented by an independent counsel, the Leading Party shall bear all of non-Leading Party’s litigation expenses (including legal fees and costs). The
Leading Party shall not have the right to settle any patent infringement litigation under this section in a manner that diminishes the rights or interests of the non-Leading Party without the prior written consent of the non-Leading Party, such
consent not to be unreasonably withheld or delayed. Any recoveries obtained by either Party shall be allocated to each Party on a pro rata basis based on the costs and expenses (including reasonable attorneys’ fees and costs) incurred in
prosecuting such enforcement action pursuant to this Section 6.3. 
 7. REPRESENTATIONS AND WARRANTIES 
 7.1 Representations and Warranties of ISI. As of the Effective Date, ISI represents and warrants to Alphatec as follows: 
 7.1.1 the execution and delivery of this Agreement and the performance of the transactions contemplated hereby have been duly authorized by all
appropriate ISI actions; 
 7.1.2 this Agreement is a legal and valid obligation binding upon ISI and enforceable in accordance with its
terms, and the execution, delivery and performance of this Agreement by the Parties does not conflict with any agreement, instrument or understanding to which ISI is a party or by which it is bound; 
 7.1.3 ISI has the full right and legal capacity to grant the rights granted to Alphatec hereunder without violating the rights of any Third Party;

 7.1.4 ISI Licensed Patents have been properly filed and prosecuted and ISI is the sole owner of the Licensed ISI Patents and the and the
materials that are the subject of the Prototype Transfer; 
  

 13 
 Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately 
 with the Secretary of the
Commission pursuant to the Registrant’s application requesting 
 confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as 
 amended. 

 7.1.5 ISI is not aware of any Third Party patent, patent application or other intellectual property
rights that would be infringed by practicing the materials that are the subject of the Prototype Transfer. 
 7.1.6 The Licensed ISI Patents
and the materials that are the subject of the Prototype Transfer represent all of the materials owned or controlled by ISI with respect to the a single-shaft Licensed Alphatec Product. 
 7.2 Representations and Warranties of Alphatec. As of the Effective Date, Alphatec represents and warrants to ISI as follows: 

7.2.1 the execution and delivery of this Agreement and the performance of the transactions contemplated hereby have been duly authorized by all
appropriate Alphatec actions; 
 7.2.2 this Agreement is a legal and valid obligation binding upon Alphatec and enforceable in accordance
with its terms, and the execution, delivery and performance of this Agreement by the Parties does not conflict with any agreement, instrument or understanding to which Alphatec is a party or by which it is bound; and 
 7.2.3 Alphatec has the full right and legal capacity to grant the rights granted to ISI hereunder without violating the rights of any Third Party.

 7.3 Representations and Warranties of each Party and Holdings. As of the Effective Date, each Party and Holdings represents
and warrants as follows: 
 7.3.1 the execution, delivery and performance of this Agreement will not constitute a violation, be in conflict
with, or result in a breach of any agreement or contract to which it is bound; 
 7.3.2 it is a corporation or entity duly organized and
validly existing under the laws of the state or other jurisdiction of incorporation or formation; 
 7.3.3 the execution, delivery and
performance of this Agreement by it has been duly authorized by all requisite corporate action and do not require any shareholder action or approval; 
 7.3.4 it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder; and 
 7.3.5 it shall at all times comply with all applicable material laws and regulations relating to its activities under the Agreement 
 7.4 No Warranties. Nothing in this Agreement is or shall be construed as a warranty or representation that anything made, used, sold or otherwise disposed of under any license granted pursuant to this
Agreement is or will be free from infringement of 

  

 14 
 Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately 
 with the Secretary of the
Commission pursuant to the Registrant’s application requesting 
 confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as 
 amended. 

 
patents, copyrights, and other rights of Third Parties. EXCEPT AS EXPRESSLY SET FORTH IN THIS SECTION 7, EACH PARTY EXCLUDES ALL OTHER REPRESENTATIONS
AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING AMONG SUCH EXCLUDED REPRESENTATIONS AND WARRANTIES ANY AND ALL REPRESENTATIONS OR WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 
 8. INDEMNIFICATION 
 8.1
Indemnification. 
 8.1.1 Indemnification by Alphatec. Alphatec shall indemnify, defend and hold harmless ISI, its
Affiliates and their respective directors, officers, employees, stockholders and agents and their respective successors, heirs and assigns (the “ISI Indemnitees”) from and against any claims, liability, damage, loss or expense (including
reasonable attorneys’ fees and expenses of litigation) (“Losses”) incurred by or imposed upon such ISI Indemnitee, or any of them, in connection with any Third Party claims, suits, actions, demands or judgments to the extent arising
out of or related to (i) the design, development, testing, production, manufacture, supply, promotion, marketing, importation, sale, use or instructions for use of any Licensed Alphatec Product (or any component thereof) manufactured or sold by
Alphatec or any Affiliate or Sublicensee under this Agreement, including without limitation any claims that (a) the design of any Licensed Alphatec Product by Alphatec infringed the intellectual property right of any Third Party or (b) any
Licensed Alphatec Product manufactured or sold by Alphatec or any Affiliate or Sublicensee under this Agreement caused the death of any person or any injury to any person or property, (ii) any material breach of any representation or warranty
by Alphatec in Article 7 of this Agreement; or (iii) the gross negligence, willful misconduct or material breach of this Agreement by Alphatec. Notwithstanding anything to the contrary stated above, except with respect to Losses that arise from
(i) Alphatec’s breach of Section 7.2; (ii) Holding’s breach of Section 7.3.1 or 7.3.4; or (ii) Alphatec’s gross negligence or willful misconduct, Alphatec’s total maximum indemnification obligation
pursuant to this Section 8.1.1 shall be limited to [***]. 
 8.1.2 Indemnification by ISI. ISI shall indemnify,
defend and hold harmless Alphatec, its Affiliates and their respective directors, officers, employees, stockholders and agents and their respective successors, heirs and assigns (the “Alphatec Indemnitees”) from and against any Losses
incurred by or imposed upon such Alphatec Indemnitee, or any of them, in connection with any Third Party claims, suits, actions, demands or judgments to the extent arising out of (i) any material breach of any representation or warranty by ISI
in Article 7 of this Agreement; or (ii) the gross negligence, willful misconduct or material breach of this Agreement by ISI. Notwithstanding anything to the contrary stated above, except with respect to Losses that arise from
(i) ISI’s breach of Section 7.1.2 and 7.1.3; or (ii) ISI’s gross negligence or willful misconduct, ISI’s total maximum indemnification obligation pursuant to this Section 8.1.2 shall be limited to
[***]. 
  

 15 
 Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately 
 with the Secretary of the
Commission pursuant to the Registrant’s application requesting 
 confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as 
 amended. 

 8.2 Indemnification Procedures. In the event that any Indemnitee is seeking indemnification under
Subsection 8.1 above from a Party (the “Indemnifying Party”), the Indemnitee shall notify the Indemnifying Party of such claim with respect to such Indemnitee as soon as reasonably practicable after the Indemnitee receives notice of
the claim, and the Party seeking indemnification, on behalf of itself and such Indemnitee, shall permit the Indemnifying Party to assume direction and control of the defense of the claim (including the right to settle the claim solely for monetary
consideration) and shall cooperate as requested (at the expense of the Indemnifying Party) in the defense of the claim. The indemnification obligations under Article 8 shall not apply to any harm suffered as a direct result of any delay in notice to
the Indemnifying Party hereunder or to amounts paid in settlement of any claim, demand, action or other proceeding if such settlement is effected without the consent of the Indemnifying Party, which consent shall not be withheld or delayed
unreasonably. The Indemnitee, its employees and agents, shall reasonably cooperate with the Indemnifying Party and its legal representatives in the investigation of any claim, demand, action or other proceeding covered by Subsection 8.1.

 9. TERM AND TERMINATION 
 9.1 Expiration. The term of this Agreement shall commence on the Effective Date and expire when the last Valid Claim of the Licensed ISI Patents is denied or expires (the “Term”). Following the Term, the license
granted (i) to Alphatec in Section 2.1, and (ii) to ISI in Section 2.2, each shall remain in full force and effect and irrevocable. 
 9.2 Termination Rights for Breach. 
 9.2.1 Termination for Breach. Subject to the other
terms of this Agreement, this Agreement and the rights granted herein may be terminated by either Party upon any material breach by the other Party of any material obligation or condition, effective ninety (90) days after giving written notice
to the breaching Party of such termination, which notice shall describe such breach in reasonable detail. The foregoing notwithstanding, if such material breach is cured or remedied or shown to be non-existent or not to be material within the
aforesaid ninety (90) day period, the notice shall be automatically withdrawn and of no effect. 
 9.2.2 Voluntary Termination.
Alphatec shall have the right to terminate this Agreement upon not less than ninety (90) days prior written notice to ISI. 
 9.2.3
ISI’s Termination Rights Based on Development Progress. In the event that the First Commercial Sale has not occurred within [***] of the Effective Date, then ISI shall be entitled to terminate the Agreement following [***]
written notice to Alphatec. The termination right set forth in this Section 9.2.3 shall not be applicable in the event that Alphatec’s inability to reach the deadline set forth in this Section 9.2.3 are primarily due to ISI’s
breach of its obligations under this Agreement. In addition, if during the [***] notice period in the first sentence of this Section 9.2.3, Alphatec (i) completes the First Commercial Sale, or (ii) gives ISI written notice that
it desires to continue this Agreement (the “Continuation Notice”), such termination shall be ineffective and void ab initio. In the event Alphatec sends the Continuation Notice, Alphatec hereby agrees to make the following payments
to ISI (each 

  

 16 
 Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately 
 with the Secretary of the
Commission pursuant to the Registrant’s application requesting 
 confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as 
 amended. 

 
of which shall be credited against any amounts due to ISI pursuant to Section 4.1.4), [***], on the anniversary of the first twelve (12)-month
period following the date of the Continuation Notice. Each subsequent twelve (12)-month period after the date of the Continuation Notice shall be treated in the same manner. If during the period following the delivery of the Continuation Notice,
Alphatec completes the First Commercial Sale, the payment amounts set forth in this Section 9.2.3 shall not be in effect following the date of such First Commercial Sale. If the payment amounts set forth in this Section 9.2.3 are not made
by Alphatec, the termination of this Agreement shall be effective without further action by the Parties. 
 9.3 Effects of
Termination 
 9.3.1 Termination Pursuant to Section 9.2.1. Upon any termination of this Agreement pursuant to
Section 9.2.1, as of the effective date of such termination all relevant licenses and sublicenses granted pursuant to this Agreement shall terminate automatically. Notwithstanding the foregoing, each Party and its Affiliates and Sublicensees
shall have the right, for [***] or such longer time period on which the Parties mutually agree in writing, to sell or otherwise dispose of all products then on hand that are being sold pursuant to the licenses granted pursuant to this
Agreement. 
 9.3.2 Termination Pursuant to Sections 9.2.2 or 9.2.3. Upon any termination of this Agreement pursuant to
Section 9.2.2 or 9.2.3, as of the effective date of such termination all relevant licenses and sublicenses granted pursuant to this Agreement shall terminate automatically. Notwithstanding the foregoing: (i) each Party and its Affiliates
and Sublicensees shall have the right, for [***] or such longer time period on which the Parties mutually agree in writing, to sell or otherwise dispose of all products then on hand that are being sold pursuant to the licenses granted
pursuant to this Agreement; and (ii) upon the written election of ISI, and upon the repayment of [***] the license granted to ISI in Section 2.2, shall remain in full force and effect and irrevocable; provided that the written
election and the payment occurs within five (5) business days of the effective date of such termination. 
 9.4 Remedies.
Except as otherwise expressly set forth in this Agreement, the termination provisions of this Article 9 are in addition to any other relief and remedies available to either Party at law or equity. 
 9.5 Surviving Provisions. Notwithstanding any provision herein to the contrary, the rights and obligations of the Parties set forth in
Subsection 3.1.1 (with respect to Alphatec’s ownership of Alphatec Inventions and Technology as set forth therein), and Sections 4.3, 4.4.1(e), 5, 8, 9.3, 9.5, 10.1, 10.2, 11.1, 11.2, 11.4 and 11.15 shall survive the expiration or termination
of this Agreement. 
  

 17 
 Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately 
 with the Secretary of the
Commission pursuant to the Registrant’s application requesting 
 confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as 
 amended. 

 10. DISPUTES 
 10.1 Negotiation. The Parties recognize that a bona fide dispute as to certain matters may from time to time arise during the term of this Agreement that relates to either Party’s rights and/or
obligations hereunder. In the event of the occurrence of such a dispute, either Party may, by written notice to the other Party, have such dispute referred to their respective senior officials designated below or their successors, for attempted
resolution by good faith negotiations within sixty (60) days after such notice is received. Said designated senior officials are as follows: 
 For Alphatec: President and Chief Executive Officer 
 For ISI: Joseph Aferzon, M.D., Manager 
 In the event the designated senior officials are not able to resolve such dispute within the sixty (60) day period, either Party may invoke the provisions of
Section 10.2. 
 10.2 Arbitration. Subject to Section 10.1, any dispute, controversy or claim initiated by either
Party arising out of, resulting from or relating to this Agreement, or the performance by either Party of its obligations under this Agreement (other than bona fide Third Party actions or proceedings filed or instituted in an action or proceeding by
a Third Party against a Party), whether before or after termination of this Agreement, shall be finally resolved by binding arbitration. Whenever a Party shall decide to institute arbitration proceedings, it shall give written notice to that effect
to the other Party. Any such arbitration shall be conducted under the Commercial Arbitration Rules of the American Arbitration Association by one arbitrator appointed in accordance with such rules. Any such arbitration shall be held in San Diego,
California. The method and manner of discovery in any such arbitration proceeding shall be governed by the laws of the State of California. The arbitrator shall have the authority to grant injunctions and/or specific performance and to
allocate between the parties the costs of arbitration in such equitable manner as they determine. Judgment upon the award so rendered may be entered in any court having jurisdiction or application may be made to such court for judicial acceptance of
any award and an order of enforcement, as the case may be. In no event shall a demand for arbitration be made after the date when institution of a legal or equitable proceeding based upon such claim, dispute or other matter in question would be
barred by the applicable statute of limitations. Notwithstanding the foregoing, either Party shall have the right, without waiving any right or remedy available to such Party under this Agreement or otherwise, to seek and obtain from any court of
competent jurisdiction any interim or provisional relief that is necessary or desirable to protect the rights or property of such Party, pending the selection of the arbitrators hereunder or pending the arbitrators’ determination of any
dispute, controversy or claim hereunder. 
  

 18 
 Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately 
 with the Secretary of the
Commission pursuant to the Registrant’s application requesting 
 confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as 
 amended. 

 11. MISCELLANEOUS 
 11.1 Notification. All notices, requests and other communications hereunder shall be in writing, shall be addressed to the receiving Party’s address set forth below or to such other address as a
Party may designate by notice hereunder, and shall be either (i) delivered by hand, (ii) sent by nationally-recognized overnight courier service providing evidence of receipt, or (iii) sent by registered or certified mail, return
receipt requested, postage prepaid. The addresses and other contact information for the parties are as follows: 
  

					
		 	If to ISI:	  	International Spinal Innovations, LLC
		 		  	97 Balfour Drive
		 		  	West Hartford, CT 06117
		 		  	Attn: Manager
			
		 	If to Alphatec:	  	Alphatec Spine, Inc.
		 		  	5818 El Camino Real
		 		  	Carlsbad, CA 92008
		 		  	Attn: President and CEO

 All notices, requests and other communications hereunder shall be deemed to
have been given either (i) if by hand, at the time of the delivery thereof to the receiving Party at the address of such Party set forth above, (ii) if made by telecopy or facsimile transmission, at the time that receipt thereof has been
acknowledged by the recipient, (iii) if sent by nationally-recognized overnight courier, on the day such notice is delivered to the recipient, or (iv) if sent by registered or certified mail, on the fifth (5th) business day following the day such mailing is made. 
 11.2 Governing Law. This Agreement will be construed and interpreted in accordance with the laws of the State of California. 
 11.3 Limitations. Except as expressly set forth in this Agreement, neither Party grants to the other Party any right or license to any of
its intellectual property. 
 11.4 Entire Agreement. This is the entire Agreement between the Parties with respect to the
subject matter hereof and supersedes all prior representations, understandings and agreements between the Parties with respect to the subject matter hereof. No modification shall be effective unless in writing with specific reference to this
Agreement and signed by the Parties. 
 11.5 Waiver. The terms or conditions of this Agreement may be waived only by a written
instrument executed by the Party waiving compliance. The failure of either Party at any time, or times, to require performance of any provision hereof shall in no manner affect its rights at a later time to enforce the same. No waiver by either
Party of any condition or term shall be deemed as a continuing waiver of such condition or term or of another condition or term. 
  

 19 
 Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately 
 with the Secretary of the
Commission pursuant to the Registrant’s application requesting 
 confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as 
 amended. 

 11.6 Headings. Section, Subsection and Paragraph headings are inserted for convenience of
reference only and do not form part of this Agreement. 
 11.7 Assignment. Neither this Agreement nor any right or obligation
hereunder may be assigned, delegated or otherwise transferred, in whole or part, by either Party without the prior express written consent of the other Party; provided that a Party may freely assign this Agreement, including all rights and
obligations hereunder, at any time to any entity acquiring in the same transaction substantially all of such Party’s business and assets, including those to which this Agreement relates, whether by way of sale, merger, consolidation or other
transaction without the prior written consent of the other Party. Any permitted assignee shall assume all obligations of its assignor under this Agreement. Any purported assignment in violation of this Section 11.7 shall be null, void, and of
no effect. The terms and conditions of this Agreement shall be binding upon and inure to the benefit of the permitted successors and assigns of the parties. 
 11.8 Force Majeure. Neither Party shall be liable for failure of or delay in performing obligations set forth in this Agreement, and neither shall be deemed in breach of its obligations, for so long as
and to the extent that such failure or delay is due to natural disasters or any causes beyond the reasonable control of such Party. In event of such force majeure, the Party affected thereby shall use reasonable efforts to cure or overcome the same
and resume performance of its obligations hereunder. 
 11.9 Construction. The Parties hereto acknowledge and agree that:
(i) each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (ii) the rule of construction to the effect that any ambiguities are resolved against the drafting
Party shall not be employed in the interpretation of this Agreement; and (iii) the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in favor of or against any Party, regardless of which Party was
generally responsible for the preparation of this Agreement. 
 11.10 Severability. If any provision(s) of this Agreement are
or become invalid, are ruled illegal by any court of competent jurisdiction or are deemed unenforceable under then current applicable law from time to time in effect during the Term hereof, it is the intention of the Parties that the remainder of
this Agreement shall not be affected thereby provided that a Party’s rights under this Agreement are not thereby materially diminished. The Parties hereto covenant and agree to renegotiate any such term, covenant or application thereof in good
faith in order to provide a reasonably acceptable alternative to the term, covenant or condition of this Agreement or the application thereof that is invalid, illegal or unenforceable, it being the intent of the Parties that the basic purposes of
this Agreement are to be effectuated. 
 11.11 Status. Nothing in this Agreement is intended or shall be deemed to constitute a
partner, agency, employer-employee, or joint venture relationship between the Parties. 
  

 20 
 Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately 
 with the Secretary of the
Commission pursuant to the Registrant’s application requesting 
 confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as 
 amended. 

 11.12 Section 365(n). All licenses granted under this Agreement are deemed to be, for
purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of right to “intellectual property” as defined in Section 101 of such Code. The Parties agree that Alphatec and ISI may fully exercise all of its rights and
elections under the U.S. Bankruptcy Code, regardless of whether either Party files for bankruptcy in the United States or other jurisdiction. 
 11.13 Further Assurances. Each Party agrees to execute, acknowledge and deliver such further instructions, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this
Agreement. 
 11.14 Counterparts. This Agreement may be executed simultaneously in one or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 11.15 Guarantee and Agreement
of Alphatec Holdings, Inc. By its signature below, Holdings hereby guarantees the full and timely payment and performance of all obligations of Alphatec under this Agreement and agrees to issue shares to ISI consistent with the terms of this
Agreement, including without limitation Section 4.4 hereof. 
 [Signature Page Follows] 
  

 21 
 Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately 
 with the Secretary of the
Commission pursuant to the Registrant’s application requesting 
 confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as 
 amended. 

 IN WITNESS WHEREOF, the Parties and Holdings have caused this Agreement to be executed by their duly
authorized representative. 
  

									
	ALPHATEC SPINE, INC.	 		 	INTERNATIONAL SPINAL INNOVATIONS, LLC
					
	By:	 	 /s/    Dirk Kuyper
	 		 	By:	 	 /s/    Joseph Aferzon, M.D.

	Name:	 	Dirk Kuyper	 		 	Name:	 	Joseph Aferzon, M.D.
	Title:	 	President and CEO	 		 	Title:	 	Manager
				
	ALPHATEC HOLDINGS, INC.	 		 		 	
					
	By:	 	 /s/    Dirk Kuyper
	 		 		 	
	Name:	 	Dirk Kuyper	 		 		 	
	Title:	 	President and CEO	 		 		 	

  

 22 
 Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately 
 with the Secretary of the
Commission pursuant to the Registrant’s application requesting 
 confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as 
 amended. 

 Schedule A 
 Licensed ISI Patents 
  

									
	 Invention Name
	 	 Application No.
	 	 Filing Date
	  	 Jurisdiction
	  	 Inventors

	 [***]
	 	[***]	 	[***]	  	[***]	  	[***]
	 [***]
	 	[***]	 	[***]	  	[***]	  	[***]

  

 23 
 Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately 
 with the Secretary of the
Commission pursuant to the Registrant’s application requesting 
 confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as 
 amended. 

 Schedule B 
 Licensed Alphatec Patents 
  

									
	 Title
	 	 Jurisdiction
	 	 Number
	  	 Inventor
	  	 Title

	 [***]
	 	[***]	 	[***]	  	[***]	  	[***]
	 [***]
	 	[***]	 	[***]	  	[***]	  	[***]

  

 24 
 Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately 
 with the Secretary of the
Commission pursuant to the Registrant’s application requesting 
 confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as 
 amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}]]